<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACTOS- pioglitazone hydrochloride tablet </strong><br>Takeda Pharmaceuticals America, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ACTOS safely and effectively. See full prescribing information for ACTOS.<br>ACTOS (pioglitazone) tablets for oral use<br>Initial U.S. Approval: 1999 </div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Thiazolidinediones, including ACTOS, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients. (<a href="#i4i_section_ID_s5.1">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">After initiation of ACTOS, and after dose increases, monitor patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (e.g., excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOS must be considered. (<a href="#i4i_section_ID_s5.1">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">ACTOS is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#i4i_warnings_precautions_ID_s5">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Initiation of ACTOS in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. (<a href="#i4i_contraindications_ID_s4">4</a>, <a href="#i4i_section_ID_s5.1">5.1</a>)</span></dd>
</dl>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning"><span class="Bold">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></span></h1>
<h1 class="Warning"><span class="Bold"><span class="Italics">See full prescribing information for complete boxed warning.</span></span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Thiazolidinediones, including ACTOS, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients. (<a href="#i4i_section_ID_s5.1">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">After initiation of ACTOS, and after dose increases, monitor patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (e.g., excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOS must be considered. (<a href="#i4i_section_ID_s5.1">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">ACTOS is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#i4i_warnings_precautions_ID_s5">5.1</a>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">Initiation of ACTOS in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated. (<a href="#i4i_contraindications_ID_s4">4</a>, <a href="#i4i_section_ID_s5.1">5.1</a>)</span></dd>
</dl>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ACTOS is a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. (<a href="#ID_aa55df2a-6d3a-4c53-9e67-4cb6082d7df9">1</a>, <a href="#i4i_clinical_studies_ID_s14">14</a>) </p>
<p class="Highlighta">  </p>
<p class="Highlighta">Important Limitations of Use: </p>
<dl>
<dt>•</dt>
<dd>Not for treatment of type 1 diabetes or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>. (<a href="#ID_aa55df2a-6d3a-4c53-9e67-4cb6082d7df9">1)</a>
</dd>
</dl>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>Initiate ACTOS at 15 mg or 30 mg once daily. Limit initial dose to 15 mg once daily in patients with NYHA Class I or II <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. (<a href="#i4i_section_ID_s2.1">2.1</a>)</dd>
<dt>•</dt>
<dd>If there is inadequate glycemic control, the dose can be increased in 15 mg increments up to a maximum of 45 mg once daily. (<a href="#i4i_section_ID_s2.1">2.1</a>)</dd>
<dt>•</dt>
<dd>Obtain liver tests before starting ACTOS. If abnormal, use caution when treating with ACTOS, investigate the probable cause, treat (if possible) and follow appropriately. Monitoring liver tests while on ACTOS is not recommended in patients without liver disease. (<a href="#i4i_section_ID_s5.3">5.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 15 mg, 30 mg, and 45 mg (<a href="#i4i_dosage_form_strength_ID_s3">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Initiation in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> <span class="Italics">[see <a href="#i4i_boxed_warning_ID_box">Boxed Warning</a>]</span>. (<a href="#i4i_contraindications_ID_s4">4</a>)</dd>
<dt>•</dt>
<dd>Use in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to pioglitazone or any other component of ACTOS. (<a href="#i4i_contraindications_ID_s4">4</a>)</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span>: <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> may occur and can exacerbate or lead to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Combination use with insulin and use in <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> NYHA Class I and II may increase risk. Monitor patients for signs and symptoms. (<a href="#i4i_section_ID_s5.1">5.1</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>: When used with insulin or an insulin secretagogue, a lower dose of the insulin or insulin secretagogue may be needed to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.(<a href="#i4i_section_ID_s5.2">5.2</a>)</dd>
<dt>•</dt>
<dd>Hepatic effects: Postmarketing reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, sometimes fatal. Causality cannot be excluded. If <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is detected, promptly interrupt ACTOS and assess patient for probable cause, then treat cause if possible, to resolution or stabilization. Do not restart ACTOS if <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is confirmed and no alternate etiology can be found. (<a href="#i4i_section_ID_s5.3">5.3</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">Bladder cancer</span>: Preclinical and clinical trial data, and results from an observational study suggest an increased risk of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in pioglitazone users. The observational data further suggest that the risk increases with duration of use. Do not use in patients with active <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. Use caution when using in patients with a prior history of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. (<a href="#i4i_warnings_precautions_ID_s5">5.4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>: Dose-related <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> may occur. (<a href="#i4i_warnings_precautions_ID_s5">5.5</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span>: Increased incidence in female patients. Apply current standards of care for assessing and maintaining bone health. (<a href="#i4i_section_ID_s5.6">5.6</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span>: Postmarketing reports. Recommend regular eye exams in all patients with diabetes according to current standards of care with prompt evaluation for acute visual changes. (<a href="#i4i_section_ID_s5.7">5.7</a>)</dd>
<dt>•</dt>
<dd>Macrovascular outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ACTOS or any other antidiabetic drug. (<a href="#i4i_section_ID_s5.9">5.9</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (≥5%) are <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>. (<a href="#i4i_section_ID_s6.1">6.1</a>) </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Takeda Pharmaceuticals at 1-877-825-3327 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Strong CYP2C8 inhibitors (e.g., gemfibrozil) increase pioglitazone concentrations. Limit ACTOS dose to 15 mg daily. (<a href="#i4i_section_ID_s2.3">2.3</a>, <a href="#i4i_section_ID_s7.1">7.1</a>)</dd>
<dt>•</dt>
<dd>CYP2C8 inducers (e.g., rifampin) may decrease pioglitazone concentrations. (<a href="#i4i_section_ID_s7.2">7.2</a>)</dd>
</dl></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Nursing mothers: Discontinue drug or nursing, taking into consideration the importance of the drug to the mother. (<a href="#i4i_nursing_mothers_ID_s8.3">8.3</a>)</dd>
<dt>•</dt>
<dd>Pediatrics: Not recommended for use in pediatric patients. (<a href="#i4i_specific_populations_ID_s8">8.4</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 11/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommendations for All Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Concomitant Use with an Insulin Secretagogue or Insulin</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Concomitant Use with Strong CYP2C8 Inhibitors</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Hepatic Effects</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Urinary Bladder Tumors</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Ovulation</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Macrovascular Outcomes</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience </a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Strong CYP2C8 Inhibitors</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 CYP2C8 Inducers</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Monotherapy </a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Combination Therapy</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="i4i_boxed_warning_ID_box"></a><a name="section-1"></a><p></p>
<h1>WARNING: <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">CONGESTIVE HEART FAILURE</span></h1>
<dl>
<dt>•</dt>
<dd><span class="Bold">Thiazolidinediones, including ACTOS, cause or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in some patients <span class="Italics">[see <a href="#i4i_section_ID_s5.1">Warnings and Precautions (5.1)</a>]</span>. </span></dd>
<dt>•</dt>
<dd><span class="Bold">After initiation of ACTOS, and after dose increases, monitor patients carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (e.g., excessive, rapid <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and/or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>). If <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOS must be considered. </span></dd>
<dt>•</dt>
<dd><span class="Bold">ACTOS is not recommended in patients with symptomatic <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. </span></dd>
<dt>•</dt>
<dd><span class="Bold">Initiation of ACTOS in patients with established New York Heart Association (NYHA) Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> is contraindicated <span class="Italics">[see <a href="#i4i_contraindications_ID_s4">Contraindications (4)</a> and <a href="#i4i_section_ID_s5.1">Warnings and Precautions (5.1)</a>]</span>.</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_aa55df2a-6d3a-4c53-9e67-4cb6082d7df9"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">Monotherapy and Combination Therapy</span></p>
<p>ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings <span class="Italics">[see <a href="#i4i_clinical_studies_ID_s14">Clinical Studies (14)</a>]</span>.</p>
<p><span class="Bold">Important Limitations of Use</span></p>
<p>ACTOS exerts its antihyperglycemic effect only in the presence of endogenous insulin. ACTOS should not be used to treat type 1 diabetes or <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span>, as it would not be effective in these settings.</p>
<p>Use caution in patients with liver disease <span class="Italics">[see <a href="#i4i_section_ID_s5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommendations for All Patients</h2>
<p class="First">ACTOS should be taken once daily and can be taken without regard to meals.</p>
<p>The recommended starting dose for patients without <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> is 15 mg or 30 mg once daily.</p>
<p>The recommended starting dose for patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (NYHA Class I or II) is 15 mg once daily.</p>
<p>The dose can be titrated in increments of 15 mg up to a maximum of 45 mg once daily based on glycemic response as determined by HbA1c.</p>
<p>After initiation of ACTOS or with dose increase, monitor patients carefully for adverse reactions related to <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> such as <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> <span class="Italics">[see<a href="#i4i_boxed_warning_ID_box"> Boxed Warning</a> and </span><span class="Italics"><a href="#i4i_warnings_precautions_ID_s5">Warnings and Precautions (5.5)</a></span><span class="Italics">]</span>.</p>
<p>Liver tests (serum alanine and <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferases</span>, alkaline phosphatase, and total bilirubin) should be obtained prior to initiating ACTOS. Routine periodic monitoring of liver tests during treatment with ACTOS is not recommended in patients without liver disease. Patients who have liver test abnormalities prior to initiation of ACTOS or who are found to have abnormal liver tests while taking ACTOS should be managed as described under Warnings and Precautions <span class="Italics">[see <a href="#i4i_section_ID_s5.3">Warnings and Precautions (5.3)</a> and<a href="#i4i_pharmacokinetics_ID_s12.3"> Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Concomitant Use with an Insulin Secretagogue or Insulin</h2>
<p class="First">If <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> occurs in a patient co-administered ACTOS and an insulin secretagogue (e.g., sulfonylurea), the dose of the insulin secretagogue should be reduced.</p>
<p>If <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> occurs in a patient co-administered ACTOS and insulin, the dose of insulin should be decreased by 10% to 25%. Further adjustments to the insulin dose should be individualized based on glycemic response.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Concomitant Use with Strong CYP2C8 Inhibitors</h2>
<p class="First">Coadministration of ACTOS and gemfibrozil, a strong CYP2C8 inhibitor, increases pioglitazone exposure approximately 3-fold. Therefore, the maximum recommended dose of ACTOS is 15 mg daily when used in combination with gemfibrozil or other strong CYP2C8 inhibitors <span class="Italics">[see <a href="#i4i_section_ID_s7.1">Drug Interactions (7.1)</a> and <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="i4i_dosage_form_strength_ID_s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Round tablet contains pioglitazone as follows:</p>
<dl>
<dt>•</dt>
<dd>15 mg: White to off-white, debossed with "ACTOS" on one side and "15" on the other</dd>
<dt>•</dt>
<dd>30 mg: White to off-white, debossed with "ACTOS" on one side and "30" on the other</dd>
<dt>•</dt>
<dd>45 mg: White to off-white, debossed with "ACTOS" on one side and "45" on the other</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<dl>
<dt>•</dt>
<dd>Initiation in patients with established NYHA Class III or IV <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> <span class="Italics">[see <a href="#i4i_boxed_warning_ID_box">Boxed Warning</a>]</span>.</dd>
<dt>•</dt>
<dd>Use in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to pioglitazone or any other component of ACTOS.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="i4i_warnings_precautions_ID_s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></h2>
<p class="First">ACTOS, like other thiazolidinediones, can cause dose-related <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> when used alone or in combination with other antidiabetic medications and is most common when ACTOS is used in combination with insulin. <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">Fluid retention</span> may lead to or exacerbate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Patients should be observed for signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. If <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> develops, it should be managed according to current standards of care and discontinuation or dose reduction of ACTOS must be considered <span class="Italics">[see <a href="#i4i_boxed_warning_ID_box">Boxed Warning</a>, <a href="#i4i_contraindications_ID_s4">Contraindications (4)</a></span>, <span class="Italics">and <a href="#i4i_section_ID_s6.1">Adverse Reactions (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></h2>
<p class="First">Patients receiving ACTOS in combination with insulin or other antidiabetic medications (particularly insulin secretagogues such as sulfonylureas) may be at risk for <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. A reduction in the dose of the concomitant antidiabetic medication may be necessary to reduce the risk of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> <span class="Italics">[see </span><span class="Italics"><a href="#ID_aa55df2a-6d3a-4c53-9e67-4cb6082d7df9">Dosage and Administration (2.2)</a></span><span class="Italics">]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Hepatic Effects</h2>
<p class="First">There have been postmarketing reports of fatal and non-fatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> in patients taking ACTOS, although the reports contain insufficient information necessary to establish the probable cause. There has been no evidence of drug-induced hepatotoxicity in the ACTOS controlled clinical trial database to date <span class="Italics">[see <a href="#i4i_section_ID_s6.1">Adverse Reactions (6.1)</a>].</span></p>
<p>Patients with type 2 diabetes may have <span class="product-label-link" type="condition" conceptid="4059290" conceptname="Steatosis of liver">fatty liver</span> disease or cardiac disease with episodic <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, both of which may cause liver test abnormalities, and they may also have other forms of liver disease, many of which can be treated or managed. Therefore, obtaining a liver test panel (serum <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> [ALT], <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">aspartate aminotransferase</span> [AST], alkaline phosphatase, and total bilirubin) and assessing the patient is recommended before initiating ACTOS therapy. In patients with abnormal liver tests, ACTOS should be initiated with caution.</p>
<p>Measure liver tests promptly in patients who report symptoms that may indicate <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, including <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, right <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">upper abdominal discomfort</span>, dark urine or <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>. In this clinical context, if the patient is found to have abnormal liver tests (ALT greater than 3 times the upper limit of the reference range), ACTOS treatment should be interrupted and investigation done to establish the probable cause. ACTOS should not be restarted in these patients without another explanation for the liver test abnormalities.</p>
<p>Patients who have serum ALT greater than three times the reference range with serum total bilirubin greater than two times the reference range without alternative etiologies are at risk for severe drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>, and should not be restarted on ACTOS. For patients with lesser elevations of serum ALT or bilirubin and with an alternate probable cause, treatment with ACTOS can be used with caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.5"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Urinary Bladder Tumors</h2>
<p class="First">Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study <span class="Italics">[<span class="Underline"><a href="#i4i_carcinogenesis_mutagenesis_fertility_ID_s13.1">see Nonclinical Toxicology (13.1)</a></span>]</span>. In two 3-year trials in which ACTOS was compared to placebo or glyburide, there were 16/3656 (0.44%) reports of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in patients taking ACTOS compared to 5/3679 (0.14%) in patients not taking ACTOS. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>, there were six (0.16%) cases on ACTOS and two (0.05%) cases on placebo.</p>
<p>A five-year interim report of an ongoing 10-year observational cohort study found a non-significant increase in the risk for <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in subjects ever exposed to ACTOS, compared to subjects never exposed to ACTOS (HR 1.2 [95% CI 0.9 –1.5]). Compared to never exposure, a duration of ACTOS therapy longer than 12 months was associated with an increase in risk (HR 1.4 [95% CI 0.9 –2.1]), which reached statistical significance after more than 24 months of ACTOS use (HR 1.4 [95% CI 1.03 –2.0]). Interim results from this study suggested that taking ACTOS longer than 12 months increased the relative risk of developing <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in any given year by 40% which equates to an absolute increase of three cases in 10,000 (from approximately seven in 10,000 [without ACTOS] to approximately 10 in 10,000 [with ACTOS]).</p>
<p>There are insufficient data to determine whether pioglitazone is a tumor promoter for urinary bladder tumors. Consequently, ACTOS should not be used in patients with active <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> and the benefits of glycemic control versus unknown risks for cancer recurrence with ACTOS should be considered in patients with a prior history of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.6"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></h2>
<p class="First">In controlled clinical trials, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> was reported more frequently in patients treated with ACTOS than in placebo-treated patients and is dose-related <span class="Italics">[see <a href="#i4i_adverse_effects_ID_s6">Adverse Reactions (6.1</a>)]</span>. In postmarketing experience, reports of new onset or worsening <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> have been received.</p>
<p>ACTOS should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>. Because thiazolidinediones, including ACTOS, can cause <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, which can exacerbate or lead to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, ACTOS should be used with caution in patients at risk for <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. Patients treated with ACTOS should be monitored for signs and symptoms of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> <span class="Italics">[see <a href="#i4i_warnings_precautions_ID_s5">Boxed Warning, Warnings, and Precautions (5.1)</a></span> <span class="Italics"><a href="#i4i_info_patients_ID_s17">and Patient Counseling Information (17)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c6e0f975-acb3-4127-8a2e-a0ba403606c4"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span></h2>
<p class="First">In PROactive (the Prospective Pioglitazone Clinical Trial in Macrovascular Events), 5238 patients with type 2 diabetes and a history of macrovascular disease were randomized to ACTOS (N=2605), force-titrated up to 45 mg daily or placebo (N=2633) in addition to standard of care. During a mean follow-up of 34.5 months, the incidence of bone <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> in females was 5.1% (44/870) for ACTOS versus 2.5% (23/905) for placebo. This difference was noted after the first year of treatment and persisted during the course of the study. The majority of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> observed in female patients were nonvertebral <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span> including lower limb and distal upper limb. No increase in the incidence of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> was observed in men treated with ACTOS (1.7%) versus placebo (2.1%). The risk of <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> should be considered in the care of patients, especially female patients, treated with ACTOS and attention should be given to assessing and maintaining bone health according to current standards of care.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular Edema</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">Macular edema</span> has been reported in postmarketing experience in diabetic patients who were taking ACTOS or another thiazolidinedione. Some patients presented with <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span> or decreased visual acuity, but others were diagnosed on routine ophthalmologic examination.</p>
<p>Most patients had <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span> at the time <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> was diagnosed. Some patients had improvement in their <span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span> after discontinuation of the thiazolidinedione.</p>
<p>Patients with diabetes should have regular eye exams by an ophthalmologist according to current standards of care. Patients with diabetes who report any visual symptoms should be promptly referred to an ophthalmologist, regardless of the patient's underlying medications or other physical findings <span class="Italics">[see<a href="#i4i_section_ID_s6.1"> Adverse Reactions (6.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Ovulation</h2>
<p class="First">Therapy with ACTOS, like other thiazolidinediones, may result in ovulation in some premenopausal anovulatory women. As a result, these patients may be at an increased risk for pregnancy while taking ACTOS <span class="Italics">[see<a href="#i4i_pregnancy_ID_s8.1"> Use in Specific Populations (8.1)</a>]</span>. This effect has not been investigated in clinical trials, so the frequency of this occurrence is not known. Adequate contraception in all premenopausal women treated with ACTOS is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Macrovascular Outcomes</h2>
<p class="First">There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ACTOS or any other antidiabetic drug.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_s6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed elsewhere in the labeling:</p>
<dl>
<dt>•</dt>
<dd> <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> <span class="Italics">[see <a href="#i4i_boxed_warning_ID_box">Boxed Warning</a> and <a href="#i4i_section_ID_s5.1">Warnings and Precautions (5.1)</a>]</span>
</dd>
<dt>•</dt>
<dd> <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> <span class="Italics">[see </span><span class="Italics"><a href="#i4i_section_ID_s5.2">Warnings and Precautions (5.5)</a></span><span class="Italics">]</span>
</dd>
<dt>•</dt>
<dd> <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">Fractures</span> <span class="Italics">[see </span><span class="Italics"><a href="#_5.6_Fractures">Warnings and Precautions (5.6)</a></span><span class="Italics">]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience </h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>Over 8500 patients with type 2 diabetes have been treated with ACTOS in randomized, double-blind, controlled clinical trials, including 2605 patients with type 2 diabetes and macrovascular disease treated with ACTOS in the PROactive clinical trial. In these trials, over 6000 patients have been treated with ACTOS for six months or longer, over 4500 patients have been treated with ACTOS for one year or longer, and over 3000 patients have been treated with ACTOS for at least two years.</p>
<p>In six pooled 16- to 26-week placebo-controlled monotherapy and 16- to 24-week add-on combination therapy trials, the incidence of withdrawals due to adverse events was 4.5% for patients treated with ACTOS and 5.8% for comparator-treated patients. The most common adverse events leading to withdrawal were related to inadequate glycemic control, although the incidence of these events was lower (1.5%) with ACTOS than with placebo (3.0%).</p>
<p>In the PROactive trial, the incidence of withdrawals due to adverse events was 9.0% for patients treated with ACTOS and 7.7% for placebo-treated patients. <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> was the most common serious adverse event leading to withdrawal occurring in 1.3% of patients treated with ACTOS and 0.6% of patients treated with placebo.</p>
<p><span class="Bold">Common Adverse Events: 16- to 26-Week Monotherapy Trials</span></p>
<p>A summary of the incidence and type of common adverse events reported in three pooled 16- to 26-week placebo-controlled monotherapy trials of ACTOS is provided in Table 1. Terms that are reported represent those that occurred at an incidence of &gt;5% and more commonly in patients treated with ACTOS than in patients who received placebo. None of these adverse events were related to ACTOS dose.</p>
<table>
<col width="67%">
<col width="24%">
<col width="24%">
<thead>
<tr class="First Toprule"><th class="Botrule" colspan="3">Table 1. Three Pooled 16- to 26-Week Placebo-Controlled Clinical Trials of ACTOS Monotherapy: Adverse Events Reported at an Incidence &gt;5% and More Commonly in Patients Treated with ACTOS than in Patients Treated with Placebo</th></tr>
<tr><th class="Botrule Lrule Rrule Toprule" colspan="3"><span class="Bold">% of Patients</span></th></tr>
<tr class="Last">
<th class="Botrule Lrule Rrule Toprule"></th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">Placebo</span><br>N=259</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">ACTOS</span><br>N=606</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">8.5</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">13.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.4</p></td>
</tr>
<tr class="Botrule Last">
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.1</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Common Adverse Events: 16- to 24-Week Add-on Combination Therapy Trials</span></p>
<p>A summary of the overall incidence and types of common adverse events reported in trials of ACTOS add-on to sulfonylurea is provided in Table 2. Terms that are reported represent those that occurred at an incidence of &gt;5% and more commonly with the highest tested dose of ACTOS.</p>
<table>
<col width="22%">
<col width="31%">
<col width="31%">
<col width="31%">
<tbody class="Headless">
<tr class="First"><td class="Botrule" colspan="4" valign="middle"><p class="First"><span class="Bold">Table 2. 16- to 24-Week Clinical Trials of ACTOS Add-on to Sulfonylurea</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">16-Week Placebo-Controlled Trial</span><br><span class="Bold">Adverse Events Reported in &gt;5% of Patients and More Commonly in Patients Treated with ACTOS 30 mg + Sulfonylurea than in Patients Treated with Placebo + Sulfonylurea</span></p></td>
</tr>
<tr><td class="Botrule Rrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+ Sulfonylurea</span><br>N=187</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 15 mg</span><br><span class="Bold">+ Sulfonylurea</span><br>N=184</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 30 mg</span><br><span class="Bold">+ Sulfonylurea</span><br>N=189</p></td>
</tr>
<tr>
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3.7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.5</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increased</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">2.7</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">5.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="3" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">24-Week Non-Controlled Double-Blind Trial</span><br><span class="Bold">Adverse Events Reported in &gt;5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Sulfonylurea than in Patients Treated with ACTOS 30 mg + Sulfonylurea</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">ACTOS 30 mg</span><br><span class="Bold">+ Sulfonylurea</span><br>N=351</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 45 mg</span><br><span class="Bold">+ Sulfonylurea</span><br>N=351</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">13.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">15.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">10.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">23.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">12.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">14.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increased</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">9.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">13.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">5.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6.8</p></td>
</tr>
<tr class="Last"><td class="Botrule Rrule" colspan="4" valign="top"><p class="First">Note: The preferred terms of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">pitting edema</span> and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> were combined to form the aggregate term of "<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>."</p></td></tr>
</tbody>
</table>
<p>A summary of the overall incidence and types of common adverse events reported in trials of ACTOS add-on to metformin is provided in Table 3. Terms that are reported represent those that occurred at an incidence of &gt;5% and more commonly with the highest tested dose of ACTOS.</p>
<table>
<col width="24%">
<col width="46%">
<col width="46%">
<thead><tr class="First Last"><th class="Botrule" colspan="3">Table 3. 16- to 24-Week Clinical Trials of ACTOS Add-on to Metformin</th></tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule" rowspan="3" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">16-Week Placebo-Controlled Trial</span><br><span class="Bold">Adverse Events Reported in &gt;5% of Patients and More Commonly in Patients Treated with ACTOS + Metformin than in Patients Treated with Placebo + Metformin</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+ Metformin</span><br>N=160</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 30 mg</span><br><span class="Bold">+ Metformin</span><br>N=168</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">24-Week Non-Controlled Double-Blind Trial</span></p>
<p><span class="Bold">Adverse Events Reported in &gt;5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Metformin than in Patients Treated with ACTOS 30 mg + Metformin</span></p>
</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 30 mg</span><br><span class="Bold">+ Metformin</span><br>N=411</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 45 mg</span><br><span class="Bold">+ Metformin</span><br>N=416</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">12.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">13.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">5.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">13.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">5.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increased</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">2.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6.7</p></td>
</tr>
<tr class="Last"><td class="Botrule Rrule" colspan="3" valign="top"><p class="First">Note: The preferred terms of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">pitting edema</span> and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> were combined to form the aggregate term of "<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>."</p></td></tr>
</tbody>
</table>
<p>Table 4 summarizes the incidence and types of common adverse events reported in trials of ACTOS add-on to insulin. Terms that are reported represent those that occurred at an incidence of &gt;5% and more commonly with the highest tested dose of ACTOS.</p>
<table>
<col width="16%">
<col width="20%">
<col width="38%">
<col width="41%">
<tbody class="Headless">
<tr class="First"><td class="Botrule" colspan="4" valign="middle"><p class="First"><span class="Bold">Table 4. 16- to 24-Week Clinical Trials of ACTOS Add-on to Insulin</span></p></td></tr>
<tr>
<td class="Botrule Lrule Toprule" rowspan="3" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">16-Week Placebo-Controlled Trial</span><br><span class="Bold">Adverse Events Reported in &gt;5% of Patients and More Commonly in Patients Treated with ACTOS 30 mg + Insulin than in Patients Treated with Placebo + Insulin</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+ Insulin</span><br>N=187</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">ACTOS 15 mg</span><br><span class="Bold">+ Insulin</span><br>N=191</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First"><span class="Bold">ACTOS 30 mg</span><br><span class="Bold">+ Insulin</span><br>N=188</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">4.8</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">7.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">15.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">7.0</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">12.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">17.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper Respiratory Tract Infection</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">9.6</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">8.4</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">14.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">3.2</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">3.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increased</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">0.5</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">5.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">4.3</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">2.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">3.7</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">2.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">1.6</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">3.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">24-Week Non-Controlled Double-Blind Trial</span><br><span class="Bold">Adverse Events Reported in &gt;5% of Patients and More Commonly in Patients Treated with ACTOS 45 mg + Insulin than in Patients Treated with ACTOS 30 mg + Insulin</span></p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">% of Patients</span></p></td></tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">ACTOS 30 mg</span><br><span class="Bold">+ Insulin</span><br>N=345</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 45 mg</span><br><span class="Bold">+ Insulin</span><br>N=345</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">43.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">47.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">22.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">26.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Increased</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">7.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">13.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infection</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">4.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">8.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">5.5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">3.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">6.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4294804" conceptname="Creatine kinase">Blood Creatine Phosphokinase</span> Increased</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">4.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">4.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">4.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">5.5</p></td>
</tr>
<tr class="Last"><td class="Botrule Rrule" colspan="4" valign="top"><p class="First">Note: The preferred terms of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">pitting edema</span> and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> were combined to form the aggregate term of "<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>."</p></td></tr>
</tbody>
</table>
<p>A summary of the overall incidence and types of common adverse events reported in the PROactive trial is provided in Table 5. Terms that are reported represent those that occurred at an incidence of &gt;5% and more commonly in patients treated with ACTOS than in patients who received placebo.</p>
<table>
<col width="55%">
<col width="30%">
<col width="31%">
<thead>
<tr class="First"><th class="Botrule" colspan="3"><span class="Bold">Table 5. PROactive Trial: Incidence and Types of Adverse Events Reported in &gt;5% of Patients Treated with ACTOS and More Commonly than Placebo</span></th></tr>
<tr>
<th class="Botrule Lrule Toprule" rowspan="2"></th>
<th class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">% of Patients</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule">
<span class="Bold">Placebo</span><br>N=2633</th>
<th class="Botrule Lrule Rrule">
<span class="Bold">ACTOS</span><br>N=2605</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">18.8</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">27.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">15.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">26.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">8.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in Extremity</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5.7</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.4</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back Pain</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5.1</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5.1</p></td>
</tr>
<tr class="Last"><td class="Botrule Rrule" colspan="3" valign="top"><p class="First">Mean duration of patient follow-up was 34.5 months.</p></td></tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></span></span></p>
<p>A summary of the incidence of adverse events related to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> is provided in Table 6 for the 16- to 24-week add-on to sulfonylurea trials, for the 16- to 24-week add-on to insulin trials, and for the 16- to 24-week add-on to metformin trials. None of the events were fatal.</p>
<table>
<col width="33%">
<col width="16%">
<col width="16%">
<col width="17%">
<col width="16%">
<col width="16%">
<tbody class="Headless">
<tr class="First"><td class="Botrule" colspan="6" valign="middle"><p class="First"><span class="Bold">Table 6. Treatment-Emergent Adverse Events of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (CHF)</span></p></td></tr>
<tr><td class="Botrule Lrule Rrule Toprule" colspan="6" valign="top"><p class="First"><span class="Bold">Patients Treated with ACTOS or Placebo Added on to a Sulfonylurea</span></p></td></tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="5" valign="top"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Placebo-Controlled Trial</span><br><span class="Bold">(16 weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top">
<p class="First"><span class="Bold">Non-Controlled</span></p>
<p><span class="Bold">Double-Blind Trial</span><br><span class="Bold">(24 weeks)</span></p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+ Sulfonylurea</span><br>N=187</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 15 mg</span><br><span class="Bold">+ Sulfonylurea</span><br>N=184</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 30 mg</span><br><span class="Bold"> + Sulfonylurea</span><br>N=189</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 30 mg </span><br><span class="Bold">+ Sulfonylurea</span><br>N=351</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 45 mg</span><br><span class="Bold">+ Sulfonylurea</span><br>N=351</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">At least one congestive<br><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> event</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2 (1.1%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1 (0.3%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6 (1.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Hospitalized</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2 (1.1%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">2 (0.6%)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="6" valign="top"><p class="First"><span class="Bold">Patients Treated with ACTOS or Placebo Added on to Insulin</span></p></td></tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="5" valign="top"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Placebo-Controlled Trial</span><br><span class="Bold">(16 weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Non-Controlled</span><br><span class="Bold">Double-Blind Trial</span><br><span class="Bold">(24 weeks)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+ Insulin</span><br>N=187</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 15 mg</span><br><span class="Bold">+ Insulin</span><br>N=191</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 30 mg </span><br><span class="Bold">+ Insulin</span><br>N=188</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 30 mg </span><br><span class="Bold">+ Insulin</span><br>N=345</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 45 mg </span><br><span class="Bold">+ Insulin</span><br>N=345</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">At least one <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> event</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2 (1.0%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2 (1.1%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3 (0.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">5 (1.4%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Hospitalized</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2 (1.0%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1 (0.5%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1 (0.3%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 (0.9%)</p></td>
</tr>
<tr><td class="Botrule Lrule Rrule" colspan="6" valign="top"><p class="First"><span class="Bold">Patients Treated with ACTOS or Placebo Added on to Metformin</span></p></td></tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" colspan="5" valign="top"><p class="First"><span class="Bold">Number (%) of Patients</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="3" valign="top"><p class="First"><span class="Bold">Placebo-Controlled Trial</span><br><span class="Bold">(16 weeks)</span></p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Non-Controlled</span><br><span class="Bold">Double-Blind Trial</span><br><span class="Bold">(24 weeks)</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First"><span class="Bold">Placebo</span><br><span class="Bold">+ Metformin</span><br>N=160</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 30 mg</span><br><span class="Bold">+ Metformin</span><br>N=168</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 30 mg</span><br><span class="Bold"> + Metformin</span><br>N=411</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"><span class="Bold">ACTOS 45 mg</span><br><span class="Bold"> + Metformin</span><br>N=416</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">At least one <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> event</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1 (0.6%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1 (0.2%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Hospitalized</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1 (0.6%)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1 (0.2%)</p></td>
</tr>
</tbody>
</table>
<p>Patients with type 2 diabetes and NYHA class II or early class III <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> were randomized to receive 24 weeks of double-blind treatment with either ACTOS at daily doses of 30 mg to 45 mg (n=262) or glyburide at daily doses of 10 mg to 15 mg (n=256). A summary of the incidence of adverse events related to <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> reported in this study is provided in Table 7.</p>
<table>
<col width="75%">
<col width="20%">
<col width="21%">
<thead>
<tr class="First"><th class="Botrule" colspan="3">Table 7. Treatment-Emergent Adverse Events of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (CHF) in Patients with NYHA Class II or III <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> Treated with ACTOS or Glyburide</th></tr>
<tr>
<th class="Botrule Lrule Toprule" rowspan="2"></th>
<th class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Number (%) of Subjects</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule">
<span class="Bold">ACTOS</span><br>N=262</th>
<th class="Botrule Lrule Rrule">
<span class="Bold">Glyburide</span><br>N=256</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> due to cardiovascular causes (adjudicated)</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">5 (1.9%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">6 (2.3%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Overnight hospitalization for worsening CHF (adjudicated)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">26 (9.9%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">12 (4.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Emergency room visit for CHF (adjudicated)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4 (1.5%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">3 (1.2%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Patients experiencing CHF progression during study</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">35 (13.4%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">21 (8.2%)</p></td>
</tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> events leading to hospitalization that occurred during the PROactive trial are summarized in Table 8.</p>
<table>
<col width="74%">
<col width="18%">
<col width="18%">
<thead>
<tr class="First"><th class="Botrule" colspan="3">Table 8. Treatment-Emergent Adverse Events of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (CHF) in PROactive Trial</th></tr>
<tr>
<th class="Botrule Lrule Toprule" rowspan="2"></th>
<th class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Number (%) of Patients</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule">
<span class="Bold">Placebo</span><br>N=2633</th>
<th class="Botrule Lrule Rrule">
<span class="Bold">ACTOS</span><br>N=2605</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First">At least one hospitalized <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> event</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">108 (4.1%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">149 (5.7%)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Fatal</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">22 (0.8%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">25 (1.0%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Hospitalized, nonfatal</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">86 (3.3%)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">124 (4.7%)</p></td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Cardiovascular Safety</span></span></p>
<p>In the PROactive trial, 5238 patients with type 2 diabetes and a history of macrovascular disease were randomized to ACTOS (N=2605), force-titrated up to 45 mg daily or placebo (N=2633) in addition to standard of care. Almost all patients (95%) were receiving cardiovascular medications (beta blockers, ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers, nitrates, diuretics, aspirin, statins and fibrates). At baseline, patients had a mean age of 62 years, mean duration of diabetes of 9.5 years, and mean HbA1c of 8.1%. Mean duration of follow-up was 34.5 months.</p>
<p>The primary objective of this trial was to examine the effect of ACTOS on mortality and macrovascular morbidity in patients with type 2 diabetes mellitus who were at high risk for macrovascular events. The primary efficacy variable was the time to the first occurrence of any event in a cardiovascular composite endpoint that included all-cause mortality, nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI) including silent MI, <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span>, cardiac intervention including coronary artery bypass grafting or percutaneous intervention, major leg amputation above the ankle, and bypass surgery or revascularization in the leg. A total of 514 (19.7%) patients treated with ACTOS and 572 (21.7%) placebo-treated patients experienced at least one event from the primary composite endpoint (hazard ratio 0.90; 95% Confidence Interval: 0.80, 1.02; p=0.10).</p>
<p>Although there was no statistically significant difference between ACTOS and placebo for the three-year incidence of a first event within this composite, there was no increase in mortality or in total macrovascular events with ACTOS. The number of first occurrences and total individual events contributing to the primary composite endpoint is shown in Table 9.</p>
<table>
<col width="47%">
<col width="17%">
<col width="17%">
<col width="17%">
<col width="17%">
<thead>
<tr class="First"><th class="Botrule" colspan="5">Table 9. PROactive: Number of First and Total Events for Each Component within the Cardiovascular Composite Endpoint</th></tr>
<tr>
<th class="Botrule Lrule Toprule" rowspan="2"><span class="Bold">Cardiovascular Events</span></th>
<th class="Botrule Lrule Toprule" colspan="2">
<span class="Bold">Placebo</span><br><span class="Bold">N=2633</span>
</th>
<th class="Botrule Lrule Rrule Toprule" colspan="2">
<span class="Bold">ACTOS</span><br><span class="Bold">N=2605</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule">First Events<br>n (%)</th>
<th class="Botrule Lrule">Total events<br>n</th>
<th class="Botrule Lrule">First Events<br>n (%)</th>
<th class="Botrule Lrule Rrule">Total events<br>n</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First">Any event</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">572 (21.7)</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">900</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">514 (19.7)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">803</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">    All-cause mortality</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">122 (4.6)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">186</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">110 (4.2)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">177</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">    Nonfatal <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (MI)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">118 (4.5)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">157</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">105 (4.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">131</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">96 (3.6)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">119</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">76 (2.9)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">92</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">    <span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">Acute coronary syndrome</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">63 (2.4)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">78</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">42 (1.6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">65</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">    Cardiac intervention (CABG/PCI)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">101 (3.8)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">240</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">101 (3.9)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">195</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">    Major leg amputation</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">15 (0.6)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">28</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9 (0.3)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">28</p></td>
</tr>
<tr>
<td class="Lrule" valign="top"><p class="First">    Leg revascularization</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">57 (2.2)</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">92</p></td>
<td class="Lrule" align="center" valign="top"><p class="First">71 (2.7)</p></td>
<td class="Lrule Rrule" align="center" valign="top"><p class="First">115</p></td>
</tr>
<tr class="Last"><td class="Botrule Rrule" colspan="5" valign="top"><p class="First">CABG = coronary artery bypass grafting; PCI = percutaneous intervention</p></td></tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight Gain</span></span></span></p>
<p>Dose-related <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> occurs when ACTOS is used alone or in combination with other antidiabetic medications. The mechanism of <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> is unclear but probably involves a combination of <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and fat accumulation.</p>
<p>Tables 10 and 11 summarize the changes in body weight with ACTOS and placebo in the 16- to 26-week randomized, double-blind monotherapy and 16- to 24-week combination add-on therapy trials and in the PROactive trial.</p>
<table>
<col width="23%">
<col width="14%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="20%">
<thead>
<tr class="First"><th class="Botrule" colspan="6">Table 10. Weight Changes (kg) from Baseline During Randomized, Double-Blind Clinical Trials</th></tr>
<tr>
<th class="Botrule Lrule Toprule" colspan="2" rowspan="2"></th>
<th class="Botrule Lrule Toprule">
<span class="Bold">Control Group</span><br><span class="Bold">(Placebo)</span>
</th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS</span><br><span class="Bold">15 mg</span>
</th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS</span><br><span class="Bold">30 mg</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">ACTOS</span><br><span class="Bold">45 mg</span>
</th>
</tr>
<tr class="Last">
<th class="Botrule Lrule">Median<br>(25<span class="Sup">th</span>/75<span class="Sup">th </span>percentile)</th>
<th class="Botrule Lrule">Median<br>(25<span class="Sup">th</span>/75<span class="Sup">th </span>percentile)</th>
<th class="Botrule Lrule">Median<br>(25<span class="Sup">th</span>/75<span class="Sup">th </span>percentile)</th>
<th class="Botrule Lrule Rrule">Median<br>(25<span class="Sup">th</span>/75<span class="Sup">th </span>percentile)</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Monotherapy</span><br><span class="Bold">(16 to 26 weeks)</span></p></td>
<td class="Botrule Lrule Toprule" valign="top"></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">-1.4 (-2.7/0.0)<br>N=256</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">0.9 (-0.5/3.4)<br>N=79</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">1.0 (-0.9/3.4)<br>N=188</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">2.6 (0.2/5.4)<br>N=79</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"><p class="First"><br><span class="Bold">Combination Therapy</span><br><span class="Bold">(16 to 24 weeks)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Sulfonylurea</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-0.5 (-1.8/0.7)<br>N=187</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.0 (0.2/3.2)<br>N=183</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3.1 (1.1/5.4)<br>N=528</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4.1 (1.8/7.3)<br>N=333</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Metformin</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-1.4 (-3.2/0.3)<br>N=160</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N/A</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.9 (-1.3/3.2)<br>N=567</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">1.8 (-0.9/5.0)<br>N=407</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Insulin</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.2 (-1.4/1.4)<br>N=182</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">2.3 (0.5/4.3)<br>N=190</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3.3 (0.9/6.3)<br>N=522</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">4.1 (1.4/6.8)<br>N=338</p></td>
</tr>
</tbody>
</table>
<table>
<col width="38%">
<col width="38%">
<col width="38%">
<tbody class="Headless">
<tr class="First"><td class="Botrule" colspan="3" valign="top"><p class="First"><span class="Bold">Table 11. Median Change in Body Weight in Patients Treated with ACTOS Versus Patients Treated with Placebo During the Double-Blind Treatment Period in the PROactive Trial</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" rowspan="2" valign="top"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">Placebo</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle"><p class="First"><span class="Bold">ACTOS</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Median</p>
<p>(25<span class="Sup">th</span>/75<span class="Sup">th</span></p>
<p>percentile)</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">Median</p>
<p>(25<span class="Sup">th</span>/75<span class="Sup">th</span></p>
<p>percentile)</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" valign="top"><p class="First">Change from baseline to final visit (kg) </p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">-0.5 (-3.3, 2.0)</p>
<p>N=2581</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="middle">
<p class="First">+3.6 (0.0, 7.5)</p>
<p>N=2560</p>
</td>
</tr>
<tr class="Last"><td class="Toprule" colspan="3" valign="top"><p class="First">Note: Median exposure for both ACTOS and Placebo was 2.7 years.</p></td></tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></span></span></p>
<p><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> induced from taking ACTOS is reversible when ACTOS is discontinued. The <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> usually does not require hospitalization unless there is coexisting <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>. A summary of the frequency and types of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> adverse events occurring in clinical investigations of ACTOS is provided in Table 12.</p>
<table>
<col width="26%">
<col width="20%">
<col width="16%">
<col width="17%">
<col width="19%">
<col width="17%">
<thead>
<tr class="First"><th class="Botrule" colspan="6">Table 12. Adverse Events of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> in Patients Treated with ACTOS</th></tr>
<tr>
<th class="Botrule Lrule Toprule" colspan="2" rowspan="2"></th>
<th class="Botrule Lrule Rrule Toprule" colspan="4"><span class="Bold">Number (%) of Patients</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule"><span class="Bold">Placebo</span></th>
<th class="Botrule Lrule">
<span class="Bold">ACTOS</span><br><span class="Bold">15 mg</span>
</th>
<th class="Botrule Lrule">
<span class="Bold">ACTOS</span><br><span class="Bold">30 mg</span>
</th>
<th class="Botrule Lrule Rrule">
<span class="Bold">ACTOS</span><br><span class="Bold">45 mg</span>
</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule" colspan="2" valign="top"><p class="First"><span class="Bold">Monotherapy (16 to 26 weeks)</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">3 (1.2%)<br>N=259</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">2 (2.5%)<br>N= 81</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">13 (4.7%)<br>N= 275</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">11 (6.5%)<br>N=169</p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="3" valign="top"><p class="First">Combined Therapy<br>(16 to 24 weeks)</p></td>
<td class="Botrule Lrule" valign="top"><p class="First">Sulfonylurea</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4 (2.1%)<br>N=187</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3 (1.6%)<br>N=184</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">61 (11.3%)<br>N=540</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">81 (23.1%)<br>N=351</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Metformin</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4 (2.5%)<br>N=160</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N/A</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">34 (5.9%)<br>N=579</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">58 (13.9%)<br>N=416</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Insulin</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">13 (7.0%)<br>N=187</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">24 (12.6%)<br>N=191</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">109 (20.5%)<br>N=533</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">90 (26.1%)<br>N=345</p></td>
</tr>
<tr class="Last"><td class="Botrule Rrule" colspan="6" valign="top"><p class="First">Note: The preferred terms of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">pitting edema</span> and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> were combined to form the aggregate term of "<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>."</p></td></tr>
</tbody>
</table>
<table>
<col width="58%">
<col width="58%">
<thead>
<tr class="First"><th class="Botrule" colspan="2">Table 13. Adverse Events of <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> in Patients in the PROactive Trial</th></tr>
<tr><th class="Botrule Lrule Rrule Toprule" colspan="2"><span class="Bold">Number (%) of Patients</span></th></tr>
<tr class="Last">
<th class="Botrule Lrule">
<span class="Bold">Placebo</span><br>N=2633</th>
<th class="Botrule Lrule Rrule">
<span class="Bold">ACTOS</span><br>N=2605</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">419 (15.9%)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">712 (27.3%)</p></td>
</tr>
<tr class="Last"><td class="Botrule Rrule" colspan="2" valign="top"><p class="First">Note: The preferred terms of <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">edema peripheral</span>, <span class="product-label-link" type="condition" conceptid="4043107" conceptname="Anasarca">generalized edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">pitting edema</span> and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> were combined to form the aggregate term of "<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>."</p></td></tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Hepatic Effects</span></span></p>
<p>There has been no evidence of induced hepatotoxicity with ACTOS in the ACTOS controlled clinical trial database to date. One randomized, double-blind 3-year trial comparing ACTOS to glyburide as add-on to metformin and insulin therapy was specifically designed to evaluate the incidence of serum ALT elevation to greater than three times the upper limit of the reference range, measured every eight weeks for the first 48 weeks of the trial then every 12 weeks thereafter. A total of 3/1051 (0.3%) patients treated with ACTOS and 9/1046 (0.9%) patients treated with glyburide developed ALT values greater than three times the upper limit of the reference range. None of the patients treated with ACTOS in the ACTOS controlled clinical trial database to date have had a serum ALT greater than three times the upper limit of the reference range and a corresponding total bilirubin greater than two times the upper limit of the reference range, a combination predictive of the potential for severe drug-induced <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span>.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></span></span></p>
<p>In the ACTOS clinical trials, adverse events of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> were reported based on clinical judgment of the investigators and did not require confirmation with fingerstick glucose testing.</p>
<p>In the 16-week add-on to sulfonylurea trial, the incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 3.7% with ACTOS 30 mg and 0.5% with placebo. In the 16-week add-on to insulin trial, the incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was 7.9% with ACTOS 15 mg, 15.4% with ACTOS 30 mg, and 4.8% with placebo.</p>
<p>The incidence of reported <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> was higher with ACTOS 45 mg compared to ACTOS 30 mg in both the 24-week add-on to sulfonylurea trial (15.7% vs. 13.4%) and in the 24-week add-on to insulin trial (47.8% vs. 43.5%).</p>
<p>Three patients in these four trials were hospitalized due to <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>. All three patients were receiving ACTOS 30 mg (0.9%) in the 24-week add-on to insulin trial. An additional 14 patients reported severe <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> (defined as causing considerable interference with patient's usual activities) that did not require hospitalization. These patients were receiving ACTOS 45 mg in combination with sulfonylurea (n=2) or ACTOS 30 mg or 45 mg in combination with insulin (n=12).</p>
<p><span class="Bold"><span class="Italics">Urinary Bladder Tumors</span></span></p>
<p>Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study <span class="Italics">[see <a href="#i4i_carcinogenesis_mutagenesis_fertility_ID_s13.1">Nonclinical Toxicology (13.1</a>)]</span>. In two 3-year trials in which ACTOS was compared to placebo or glyburide, there were 16/3656 (0.44%) reports of <span class="product-label-link" type="condition" conceptid="197508" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> in patients taking ACTOS compared to 5/3679 (0.14%) in patients not taking ACTOS. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>, there were six (0.16%) cases on ACTOS and two (0.05%) cases on placebo. There are too few events of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> to establish causality.</p>
<p><span class="Bold">Laboratory Abnormalities</span></p>
<p><span class="Bold">Hematologic Effects</span></p>
<p>ACTOS may cause decreases in hemoglobin and hematocrit. In placebo-controlled monotherapy trials, mean hemoglobin values declined by 2% to 4% in patients treated with ACTOS compared with a mean change in hemoglobin of -1% to +1% in placebo-treated patients. These changes primarily occurred within the first 4 to 12 weeks of therapy and remained relatively constant thereafter. These changes may be related to increased plasma volume associated with ACTOS therapy and are not likely to be associated with any clinically significant hematologic effects.</p>
<p><span class="Bold">Creatine Phosphokinase</span></p>
<p>During protocol-specified measurement of serum creatine phosphokinase (CPK) in ACTOS clinical trials, an isolated elevation in CPK to greater than 10 times the upper limit of the reference range was noted in nine (0.2%) patients treated with ACTOS (values of 2150 to 11400 IU/L) and in no comparator-treated patients. Six of these nine patients continued to receive ACTOS, two patients were noted to have the CPK elevation on the last day of dosing and one patient discontinued ACTOS due to the elevation. These elevations resolved without any apparent clinical sequelae. The relationship of these events to ACTOS therapy is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s6.3"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<p class="First">The following adverse reactions have been identified during post-approval use of ACTOS. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<dl>
<dt>•</dt>
<dd>New onset or worsening <span class="product-label-link" type="condition" conceptid="380097" conceptname="Diabetic macular edema">diabetic macular edema</span> with decreased visual acuity <span class="Italics">[see </span><span class="Italics"><a href="#i4i_section_ID_s5.2">Warnings and Precautions (5.7)</a></span><span class="Italics">]</span>.</dd>
<dt>•</dt>
<dd>Fatal and nonfatal <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> <span class="Italics">[see <a href="#i4i_section_ID_s5.3">Warnings and Precautions (5.3)</a>]</span>.</dd>
</dl>
<p>Postmarketing reports of <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> have been reported in patients treated with ACTOS, both with and without previously known heart disease and both with and without concomitant insulin administration.</p>
<p>In postmarketing experience, there have been reports of unusually rapid increases in weight and increases in excess of that generally observed in clinical trials. Patients who experience such increases should be assessed for fluid accumulation and volume-related events such as excessive <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> <span class="Italics">[see <a href="#i4i_boxed_warning_ID_box">Boxed Warning </a>and <a href="#i4i_section_ID_s5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_ID_s7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Strong CYP2C8 Inhibitors</h2>
<p class="First">An inhibitor of CYP2C8 (e.g., gemfibrozil) significantly increases the exposure (area under the serum concentration-time curve or AUC) and half-life (t<span class="Sub">1/2</span>) of pioglitazone. Therefore, the maximum recommended dose of ACTOS is 15 mg daily if used in combination with gemfibrozil or other strong CYP2C8 inhibitors <span class="Italics">[see <a href="#i4i_section_ID_s2.3">Dosage and Administration (2.3)</a> and <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 CYP2C8 Inducers</h2>
<p class="First">An inducer of CYP2C8 (e.g., rifampin) may significantly decrease the exposure (AUC) of pioglitazone. Therefore, if an inducer of CYP2C8 is started or stopped during treatment with ACTOS, changes in diabetes treatment may be needed based on clinical response without exceeding the maximum recommended daily dose of 45 mg for ACTOS <span class="Italics">[see <a href="#i4i_pharmacokinetics_ID_s12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="i4i_specific_populations_ID_s8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_s8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First"><span class="Bold">Pregnancy Category C.</span></p>
<p>There are no adequate and well-controlled studies of ACTOS in pregnant women. Animal studies show increased rates of post-implantation loss, delayed development, reduced fetal weights, and delayed parturition at doses 10 to 40 times the maximum recommended human dose. ACTOS should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p><span class="Bold">Clinical Considerations</span></p>
<p>Abnormal blood glucose concentrations during pregnancy are associated with a higher incidence of congenital anomalies, as well as increased neonatal morbidity and mortality. Most experts recommend the use of insulin during pregnancy to maintain blood glucose concentrations as close to normal as possible for patients with diabetes.</p>
<p><span class="Bold">Animal Data</span></p>
<p>In animal reproductive studies, pregnant rats and rabbits received pioglitazone at doses up to approximately 17 (rat) and 40 (rabbit) times the maximum recommended human oral dose (MRHD) based on body surface area (mg/m<span class="Sup">2</span>); no <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> was observed. Increases in embryotoxicity (increased postimplantation losses, delayed development, reduced fetal weights, and delayed parturition) occurred in rats that received oral doses approximately 10 or more times the MRHD (mg/m<span class="Sup">2</span> basis). No functional or behavioral toxicity was observed in rat offspring. When pregnant rats received pioglitazone during late gestation and lactation, delayed postnatal development, attributed to decreased body weight, occurred in rat offspring at oral maternal doses approximately two or more times the MRHD (mg/m<span class="Sup">2</span> basis). In rabbits, embryotoxicity occurred at oral doses approximately 40 times the MRHD (mg/m<span class="Sup">2</span> basis). </p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_s8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether ACTOS is secreted in human milk. Pioglitazone is secreted in the milk of lactating rats. Because many drugs are excreted in human milk, and because of the potential for ACTOS to cause serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue ACTOS, taking into account the importance of ACTOS to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_s8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of ACTOS in pediatric patients have not been established.</p>
<p>ACTOS is not recommended for use in pediatric patients based on adverse effects observed in adults, including <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span> and <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>, and urinary bladder tumors <span class="Italics">[see </span><span class="Italics"><a href="#i4i_warnings_precautions_ID_s5">Warnings and Precautions (5.1, 5.4, 5.5 and 5.6)</a></span><span class="Italics">].</span></p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_ID_s8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">A total of 92 patients (15.2%) treated with ACTOS in the three pooled 16- to 26-week double-blind, placebo-controlled, monotherapy trials were ≥65 years old and two patients (0.3%) were ≥75 years old. In the two pooled 16- to 24-week add-on to sulfonylurea trials, 201 patients (18.7%) treated with ACTOS were ≥65 years old and 19 (1.8%) were ≥75 years old. In the two pooled 16- to 24-week add-on to metformin trials, 155 patients (15.5%) treated with ACTOS were ≥65 years old and 19 (1.9%) were ≥75 years old. In the two pooled 16- to 24-week add-on to insulin trials, 272 patients (25.4%) treated with ACTOS were ≥65 years old and 22 (2.1%) were ≥75 years old.</p>
<p>In PROactive, 1068 patients (41.0%) treated with ACTOS were ≥65 years old and 42 (1.6%) were ≥75 years old.</p>
<p>In pharmacokinetic studies with pioglitazone, no significant differences were observed in pharmacokinetic parameters between elderly and younger patients <span class="Italics">[</span>see<span class="Italics"><a href="#i4i_clinical_pharmacology_ID_s12"> Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>Although clinical experiences have not identified differences in effectiveness and safety between the elderly (≥65 years) and younger patients, these conclusions are limited by small sample sizes for patients ≥75 years old.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_s10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">During controlled clinical trials, one case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with ACTOS was reported. A male patient took 120 mg per day for four days, then 180 mg per day for seven days. The patient denied any clinical symptoms during this period.</p>
<p>In the event of overdosage, appropriate supportive treatment should be initiated according to the patient's clinical signs and symptoms.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_s11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">ACTOS tablets are a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma that contains an oral antidiabetic medication: pioglitazone.</p>
<p>Pioglitazone [(±)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochloride contains one asymmetric carbon, and the compound is synthesized and used as the racemic mixture. The two enantiomers of pioglitazone interconvert <span class="Italics">in vivo</span>. No differences were found in the pharmacologic activity between the two enantiomers. The structural formula is as shown:</p>
<div class="Figure">
<a name="id2398"></a><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c&amp;name=352f5dd8-4c3e-4e8e-8167-bf383bd95dd6-01.jpg">
</div>
<p>Pioglitazone hydrochloride is an odorless white crystalline powder that has a molecular formula of C<span class="Sub">19</span>H<span class="Sub">20</span>N<span class="Sub">2</span>O<span class="Sub">3</span>S•HCl and a molecular weight of 392.90 daltons. It is soluble in <span class="Italics">N,N</span>-dimethylformamide, slightly soluble in anhydrous ethanol, very slightly soluble in acetone and acetonitrile, practically insoluble in water, and insoluble in ether.</p>
<p>ACTOS is available as a tablet for oral administration containing 15 mg, 30 mg, or 45 mg of pioglitazone (as the base) formulated with the following excipients: lactose monohydrate NF, hydroxypropylcellulose NF, carboxymethylcellulose calcium NF, and magnesium stearate NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_s12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="i4i_mechanism_action_ID_s12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">ACTOS is a thiazolidinedione that depends on the presence of insulin for its mechanism of action. ACTOS decreases <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span> in the periphery and in the liver resulting in increased insulin-dependent glucose disposal and decreased hepatic glucose output. Pioglitazone is not an insulin secretagogue. Pioglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARγ). PPAR receptors are found in tissues important for insulin action such as adipose tissue, skeletal muscle, and liver. Activation of PPARγ nuclear receptors modulates the transcription of a number of insulin responsive genes involved in the control of glucose and lipid metabolism.</p>
<p>In animal models of diabetes, pioglitazone reduces the <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4307509" conceptname="Hyperinsulinism">hyperinsulinemia</span>, and <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span> characteristic of insulin-resistant states such as type 2 diabetes. The metabolic changes produced by pioglitazone result in increased responsiveness of insulin-dependent tissues and are observed in numerous animal models of <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>.</p>
<p>Because pioglitazone enhances the effects of circulating insulin (by decreasing <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span>), it does not lower blood glucose in animal models that lack endogenous insulin.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="i4i_pharmacodynamics_ID_s12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Clinical studies demonstrate that ACTOS improves insulin sensitivity in insulin-resistant patients. ACTOS enhances cellular responsiveness to insulin, increases insulin-dependent glucose disposal and improves hepatic sensitivity to insulin. In patients with type 2 diabetes, the decreased <span class="product-label-link" type="condition" conceptid="4168924" conceptname="Drug resistance to insulin">insulin resistance</span> produced by ACTOS results in lower plasma glucose concentrations, lower plasma insulin concentrations, and lower HbA1c values. In controlled clinical trials, ACTOS had an additive effect on glycemic control when used in combination with a sulfonylurea, metformin, or insulin <span class="Italics">[see <a href="#i4i_section_ID_s14.2">Clinical Studies (14.2)</a>]</span>.</p>
<p>Patients with lipid abnormalities were included in clinical trials with ACTOS. Overall, patients treated with ACTOS had mean decreases in serum triglycerides, mean increases in HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>, and no consistent mean changes in LDL and total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>. There is no conclusive evidence of macrovascular benefit with ACTOS or any other antidiabetic medication <span class="Italics">[see <a href="#i4i_section_ID_s5.9">Warnings and Precautions (5.9)</a> and <a href="#i4i_section_ID_s6.1">Adverse Reactions (6.1)</a>]</span>. </p>
<p>In a 26-week, placebo-controlled, dose-ranging monotherapy study, mean serum triglycerides decreased in the 15 mg, 30 mg, and 45 mg ACTOS dose groups compared to a mean increase in the placebo group. Mean HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> increased to a greater extent in patients treated with ACTOS than in the placebo-treated patients. There were no consistent differences for LDL and total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> in patients treated with ACTOS compared to placebo <span class="Italics">(see Table 14)</span>.</p>
<table>
<col width="46%">
<col width="10%">
<col width="13%">
<col width="13%">
<col width="13%">
<thead>
<tr class="First"><th class="Botrule" colspan="5">Table 14. Lipids in a 26-Week Placebo-Controlled Monotherapy Dose-Ranging Study</th></tr>
<tr class="Last">
<th class="Botrule Lrule Toprule"></th>
<th class="Botrule Lrule Toprule"><span class="Bold">Placebo</span></th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS</span><br><span class="Bold">15 mg</span><br><span class="Bold">Once Daily</span>
</th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS</span><br><span class="Bold">30 mg</span><br><span class="Bold">Once Daily</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">ACTOS</span><br><span class="Bold">45 mg</span><br><span class="Bold">Once Daily</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>p &lt;0.05 versus placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"><p class="First"><span class="Bold">Triglycerides (mg/dL)</span></p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">N=79</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">N=79</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">N=84</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">N=77</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">263</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">284</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">261</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">260</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Percent change from baseline (adjusted mean<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4.8%</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-9.0%<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-9.6%<a href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-9.3%<a href="#footnote-2" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">HDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=79</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=79</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=83</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=77</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">42</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">40</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">41</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">41</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Percent change from baseline (adjusted mean<a href="#footnote-1" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8.1%</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">14.1%<a href="#footnote-2" class="Sup">†</a></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">12.2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">19.1%<a href="#footnote-2" class="Sup">†</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">LDL <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=65</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=63</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=74</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=62</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">139</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">132</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">136</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">127</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Percent change from baseline (adjusted mean<a href="#footnote-1" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4.8%</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">7.2%</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">5.2%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">Cholesterol</span> (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=79</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=79</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=84</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=77</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">225</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">220</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">223</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">214</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"><p class="First">Percent change from baseline (adjusted mean<a href="#footnote-1" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4.4%</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">4.6%</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">3.3%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">6.4%</p></td>
</tr>
</tbody>
</table>
<p>In the two other monotherapy studies (16 weeks and 24 weeks) and in combination therapy studies with sulfonylurea (16 weeks and 24 weeks), metformin (16 weeks and 24 weeks) or insulin (16 weeks and 24 weeks), the results were generally consistent with the data above. </p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="i4i_pharmacokinetics_ID_s12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Following once-daily administration of ACTOS, steady-state serum concentrations of both pioglitazone and its major active metabolites, M-III (keto derivative of pioglitazone) and M-IV (hydroxyl derivative of pioglitazone), are achieved within seven days. At steady-state, M-III and M-IV reach serum concentrations equal to or greater than that of pioglitazone. At steady-state, in both healthy volunteers and patients with type 2 diabetes, pioglitazone comprises approximately 30% to 50% of the peak total pioglitazone serum concentrations (pioglitazone plus active metabolites) and 20% to 25% of the total AUC.</p>
<p>C<span class="Sub">max</span>, AUC, and trough serum concentrations (C<span class="Sub">min</span>) for pioglitazone and M-III and M-IV, increased proportionally with administered doses of 15 mg and 30 mg per day. </p>
<p><span class="Bold">Absorption</span></p>
<p>Following oral administration of pioglitazone, T<span class="Sub">max</span> of pioglitazone was within two hours. Food delays the T<span class="Sub">max</span> to three to four hours but does not alter the extent of absorption (AUC).</p>
<p><span class="Bold">Distribution</span></p>
<p>The mean apparent volume of distribution (Vd/F) of pioglitazone following single-dose administration is 0.63 ± 0.41 (mean ± SD) L/kg of body weight. Pioglitazone is extensively protein bound (&gt;99%) in human serum, principally to serum albumin. Pioglitazone also binds to other serum proteins, but with lower affinity. M-III and M-IV are also extensively bound (&gt;98%) to serum albumin.</p>
<p><span class="Bold">Metabolism</span></p>
<p>Pioglitazone is extensively metabolized by hydroxylation and oxidation; the metabolites also partly convert to glucuronide or sulfate conjugates. Metabolites M-III and M-IV are the major circulating active metabolites in humans.</p>
<p><span class="Italics">In vitro</span> data demonstrate that multiple CYP isoforms are involved in the metabolism of pioglitazone, which include CYP2C8 and, to a lesser degree, CYP3A4 with additional contributions from a variety of other isoforms including the mainly extrahepatic CYP1A1. <span class="Italics">In vivo</span> study of pioglitazone in combination with gemfibrozil, a strong CYP2C8 inhibitor, showed that pioglitazone is a CYP2C8 substrate <span class="Italics">[see <a href="#i4i_section_ID_s2.3">Dosage and Administration (2.3)</a> and <a href="#i4i_interactions_ID_s7">Drug Interactions (7)</a>]</span>. Urinary 6ß-hydroxycortisol/cortisol ratios measured in patients treated with ACTOS showed that pioglitazone is not a strong CYP3A4 enzyme inducer.</p>
<p><span class="Bold">Excretion and Elimination</span></p>
<p>Following oral administration, approximately 15% to 30% of the pioglitazone dose is recovered in the urine. Renal elimination of pioglitazone is negligible, and the drug is excreted primarily as metabolites and their conjugates. It is presumed that most of the oral dose is excreted into the bile either unchanged or as metabolites and eliminated in the feces.</p>
<p>The mean serum half-life (t<span class="Sub">1/2</span>) of pioglitazone and its metabolites (M-III and M-IV) range from three to seven hours and 16 to 24 hours, respectively. Pioglitazone has an apparent clearance, CL/F, calculated to be five to seven L/hr.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></span></p>
<p>The serum elimination half-life of pioglitazone, M-III, and M-IV remains unchanged in patients with moderate (creatinine clearance [CLcr] 30 to 50 mL/min) and severe (CLcr &lt;30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when compared to subjects with normal renal function. Therefore, no dose adjustment in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is required.</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></span></p>
<p>Compared with healthy controls, subjects with impaired hepatic function (Child-Turcotte-Pugh Grade B/C) have an approximate 45% reduction in pioglitazone and total pioglitazone (pioglitazone, M-III, and M-IV) mean C<span class="Sub">max </span>but no change in the mean AUC values. Therefore, no dose adjustment in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> is required. </p>
<p>There are postmarketing reports of <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">liver failure</span> with ACTOS and clinical trials have generally excluded patients with serum ALT &gt;2.5 times the upper limit of the reference range. Use caution in patients with liver disease <span class="Italics">[see<a href="#i4i_section_ID_s5.3"> Warnings and Precautions (5.3)</a>]</span>.</p>
<p><span class="Bold">Geriatric Patients</span></p>
<p>In healthy elderly subjects, C<span class="Sub">max </span>of pioglitazone was not significantly different, but AUC values were approximately 21% higher than those achieved in younger subjects. The mean t<span class="Sub">1/2</span> of pioglitazone was also prolonged in elderly subjects (about ten hours) as compared to younger subjects (about seven hours). These changes were not of a magnitude that would be considered clinically relevant.</p>
<p><span class="Bold">Pediatric Patients</span></p>
<p>Safety and efficacy of pioglitazone in pediatric patients have not been established. ACTOS is not recommended for use in pediatric patients <span class="Italics">[see <a href="#i4i_pediatric_use_ID_s8.4">Use in Specific Populations (8.4)</a>]</span>.</p>
<p><span class="Bold">Gender</span></p>
<p>The mean C<span class="Sub">max</span> and AUC values of pioglitazone were increased 20% to 60% in women compared to men. In controlled clinical trials, HbA1c decreases from baseline were generally greater for females than for males (average mean difference in HbA1c 0.5%). Because therapy should be individualized for each patient to achieve glycemic control, no dose adjustment is recommended based on gender alone.</p>
<p><span class="Bold">Ethnicity</span></p>
<p>Pharmacokinetic data among various ethnic groups are not available.</p>
<p><span class="Bold">Drug-Drug Interactions</span></p>
<table>
<col width="22%">
<col width="38%">
<col width="20%">
<col width="12%">
<col width="13%">
<col width="8%">
<thead>
<tr class="First"><th class="Botrule" colspan="6">Table 15. Effect of Pioglitazone Coadministration on Systemic Exposure of Other Drugs</th></tr>
<tr>
<th class="Botrule Lrule Toprule"></th>
<th class="Botrule Lrule Rrule Toprule" colspan="5"><span class="Bold">Coadministered Drug</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule">
<span class="Bold">Pioglitazone Dosage</span><br><span class="Bold">Regimen (mg)</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a>
</th>
<th class="Botrule Lrule"><span class="Bold">Name and Dose Regimens</span></th>
<th class="Botrule Lrule" colspan="2">
<span class="Bold">Change in AUC</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>
</th>
<th class="Botrule Lrule Rrule" colspan="2">
<span class="Bold">Change in C<span class="Sub">max</span></span><a href="#footnote-4" class="Sup">†</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Daily for 7 days unless otherwise noted</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>% change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd>Pioglitazone had no clinically significant effect on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule Toprule" align="center" rowspan="3" valign="middle"><p class="First">45 mg<br>(N = 12)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="5" valign="middle"><p class="First"><span class="Bold">Warfarin</span><a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a></p></td>
</tr>
<tr>
<td class="Botrule Lrule" rowspan="2" valign="middle"><p class="First">Daily loading then maintenance doses based PT and INR values Quick's Value = 35 ± 5%</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">R-Warfarin</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">↓3%</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">R-Warfarin</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↓2%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">S-Warfarin</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">↓1%</p></td>
<td class="Botrule Lrule" align="center" valign="middle"><p class="First">S-Warfarin</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="middle"><p class="First">↑1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2" valign="middle"><p class="First">45 mg<br>(N = 12)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Digoxin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">0.200 mg twice daily (loading dose) then 0.250 mg daily (maintenance dose, 7 days)</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">↑15%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↑17%</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" rowspan="3" valign="top"><p class="First">45 mg daily<br>for 21 days<br>(N = 35)</p></td>
<td class="Botrule Lrule Rrule Toprule" colspan="5" valign="middle"><p class="First"><span class="Bold">Oral Contraceptive </span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Toprule" rowspan="2" valign="middle"><p class="First">[Ethinyl Estradiol (EE) 0.035 mg plus<br>Norethindrone (NE) 1 mg] for 21 days</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">EE</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">↓11%</p></td>
<td class="Botrule Lrule Toprule" align="center" valign="top"><p class="First">EE</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"><p class="First">↓13%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">NE</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">↑3%</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">NE</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">↓7%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2" valign="top"><p class="First">45 mg<br>(N = 23)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Fexofenadine</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">60 mg twice daily for 7 days</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First">↑30%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">↑37%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2" valign="top"><p class="First">45 mg<br>(N = 14)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Glipizide</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">5 mg daily for 7 days</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First">↓3%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">↓8%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2" valign="top"><p class="First">45 mg daily<br>for 8 days<br>(N = 16)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Metformin</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">1000 mg single dose on Day 8</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">↓3%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2" valign="top"><p class="First">45 mg<br>(N = 21)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Midazolam</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">7.5 mg single dose on Day 15</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First">↓26%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">↓26%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2" valign="top"><p class="First">45 mg<br>(N = 24)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Ranitidine</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">150 mg twice daily for 7 days</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First">↑1%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">↓1%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2" valign="top"><p class="First">45 mg daily<br>for 4 days<br>(N = 24)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Nifedipine ER</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">30 mg daily for 4 days</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="middle"><p class="First">↓13%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="middle"><p class="First">↓17%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2" valign="top"><p class="First">45 mg<br>(N = 25)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Atorvastatin Ca</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">80 mg daily for 7 days</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First">↓14%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">↓23%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" rowspan="2" valign="top"><p class="First">45 mg<br>(N = 22)</p></td>
<td class="Botrule Lrule Rrule" colspan="5" valign="middle"><p class="First"><span class="Bold">Theophylline</span></p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="middle"><p class="First">400 mg twice daily for 7 days</p></td>
<td class="Botrule Lrule" align="center" colspan="2" valign="top"><p class="First">↑2%</p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="2" valign="top"><p class="First">↑5%</p></td>
</tr>
</tbody>
</table>
<table>
<col width="47%">
<col width="17%">
<col width="12%">
<col width="10%">
<thead>
<tr class="First Toprule"><th class="Botrule" colspan="4">Table 16. Effect of Coadministered Drugs on Pioglitazone Systemic Exposure</th></tr>
<tr>
<th class="Botrule Lrule Toprule" rowspan="2"><span class="Bold">Coadministered Drug and Dosage Regimen</span></th>
<th class="Botrule Lrule Rrule Toprule" colspan="3"><span class="Bold">Pioglitazone</span></th>
</tr>
<tr class="Last">
<th class="Botrule Lrule">
<span class="Bold">Dose Regimen</span><br><span class="Bold">(mg)</span><a name="footnote-reference-6" href="#footnote-6" class="Sup">*</a>
</th>
<th class="Botrule Lrule">
<span class="Bold">Change</span><br><span class="Bold">in AUC</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">†</a>
</th>
<th class="Botrule Lrule Rrule">
<span class="Bold">Change</span><br><span class="Bold">in C<span class="Sub">max</span></span><a href="#footnote-7" class="Sup">†</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-6" href="#footnote-reference-6">*</a></dt>
<dd>Daily for 7 days unless otherwise noted</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">†</a></dt>
<dd>Mean ratio (with/without coadministered drug and no change = 1-fold) % change (with/without coadministered drug and no change = 0%); symbols of ↑ and ↓ indicate the exposure increase and decrease, respectively</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">‡</a></dt>
<dd>The half-life of pioglitazone increased from 8.3 hours to 22.7 hours in the presence of gemfibrozil <span class="Italics">[see <a href="#i4i_section_ID_s2.3">Dosage and Administration (2.3)</a> and <a href="#i4i_interactions_ID_s7">Drug Interactions (7)</a>]</span>
</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Gemfibrozil 600 mg<br>twice daily for 2 days<br>(N = 12)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">15 mg<br>single dose</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">↑3.2-fold<a name="footnote-reference-8" href="#footnote-8" class="Sup">‡</a></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">↑6%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Ketoconazole 200 mg<br>twice daily for 7 days<br>(N = 28)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">↑34%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">↑14%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Rifampin 600 mg<br>daily for 5 days<br>(N = 10)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">30 mg<br>single dose</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">↓54%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">↓5%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Fexofenadine 60 mg<br>twice daily for 7 days<br>(N = 23)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">↑1%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">0%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Ranitidine 150 mg<br>twice daily for 4 days<br>(N = 23)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">↓13%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">↓16%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Nifedipine ER 30 mg<br>daily for 7 days<br>(N = 23)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">↑5%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">↑4%</p></td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Atorvastatin Ca 80 mg<br>daily for 7 days<br>(N = 24)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">↓24%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">↓31%</p></td>
</tr>
<tr class="Botrule Last">
<td class="Botrule Lrule" align="center" valign="top"><p class="First">Theophylline 400 mg<br>twice daily for 7 days<br>(N = 22)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">45 mg</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">↓4%</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">↓2%</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="i4i_nonclinical_toxicology_ID_s13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_s13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">A two-year carcinogenicity study was conducted in male and female rats at oral doses up to 63 mg/kg (approximately 14 times the maximum recommended human oral dose of 45 mg based on mg/m<span class="Sup">2</span>). Drug-induced tumors were not observed in any organ except for the urinary bladder of male rats. Benign and/or malignant transitional cell neoplasms were observed in male rats at 4 mg/kg/day and above (approximately equal to the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>). Urinary calculi with subsequent irritation and <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span> were postulated as the mechanism for bladder tumors observed in male rats. A two-year mechanistic study in male rats utilizing dietary acidification to reduce calculi formation was completed in 2009. Dietary acidification decreased but did not abolish the hyperplastic changes in the bladder. The presence of calculi exacerbated the hyperplastic response to pioglitazone but was not considered the primary cause of the hyperplastic changes.</p>
<p>The relevance to humans of the bladder findings in the male rat cannot be excluded.</p>
<p>A two-year carcinogenicity study was also conducted in male and female mice at oral doses up to 100 mg/kg/day (approximately 11 times the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>). No drug-induced tumors were observed in any organ. </p>
<p>Pioglitazone hydrochloride was not mutagenic in a battery of genetic toxicology studies, including the Ames bacterial assay, a mammalian cell forward gene mutation assay (CHO/HPRT and AS52/XPRT), an <span class="Italics">in vitro</span> cytogenetics assay using CHL cells, an unscheduled DNA synthesis assay, and an <span class="Italics">in vivo</span> micronucleus assay.</p>
<p>No adverse effects upon fertility were observed in male and female rats at oral doses up to 40 mg/kg pioglitazone hydrochloride daily prior to and throughout mating and gestation (approximately nine times the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>). </p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_ID_s13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">Heart enlargement has been observed in mice (100 mg/kg), rats (4 mg/kg and above) and dogs (3 mg/kg) treated orally with pioglitazone hydrochloride (approximately 11, 1, and 2 times the maximum recommended human oral dose for mice, rats, and dogs, respectively, based on mg/m<span class="Sup">2</span>). In a one-year rat study, drug-related early <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to apparent heart dysfunction occurred at an oral dose of 160 mg/kg/day (approximately 35 times the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>). Heart enlargement was seen in a 13-week study in monkeys at oral doses of 8.9 mg/kg and above (approximately four times the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>), but not in a 52-week study at oral doses up to 32 mg/kg (approximately 13 times the maximum recommended human oral dose based on mg/m<span class="Sup">2</span>). </p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_ID_s14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Monotherapy </h2>
<p class="First">Three randomized, double-blind, placebo-controlled trials with durations from 16 to 26 weeks were conducted to evaluate the use of ACTOS as monotherapy in patients with type 2 diabetes. These trials examined ACTOS at doses up to 45 mg or placebo once daily in a total of 865 patients. </p>
<p>In a 26-week dose-ranging monotherapy trial, 408 patients with type 2 diabetes were randomized to receive 7.5 mg, 15 mg, 30 mg, or 45 mg of ACTOS, or placebo once daily. Therapy with any previous antidiabetic agent was discontinued eight weeks prior to the double-blind period. Treatment with 15 mg, 30 mg, and 45 mg of ACTOS produced statistically significant improvements in HbA1c and fasting plasma glucose (FPG) at endpoint compared to placebo <span class="Italics">(see Figure 1, <a href="#Table17">Table 17</a>)</span>.</p>
<p>Figure 1 shows the time course for changes in HbA1c in this 26-week study.</p>
<p><span class="Bold">Figure 1. Mean Change from Baseline for HbA1c in a 26-Week Placebo-Controlled Dose-Ranging Study (Observed Values)</span></p>
<span class="Bold"><div class="Figure">
<a name="id421768"></a><img alt="Figure1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c&amp;name=352f5dd8-4c3e-4e8e-8167-bf383bd95dd6-02.jpg">
</div></span><table>
<col width="51%">
<col width="12%">
<col width="15%">
<col width="15%">
<col width="15%">
<thead>
<tr class="First Toprule"><th class="Botrule" colspan="5">Table 17. Glycemic Parameters in a 26-Week Placebo-Controlled Dose-Ranging Monotherapy Trial</th></tr>
<tr class="Last">
<th class="Botrule Lrule Toprule"></th>
<th class="Botrule Lrule Toprule"><span class="Bold">Placebo</span></th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS</span><br><span class="Bold">15 mg</span><br><span class="Bold">Once</span><br><span class="Bold">Daily</span>
</th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS</span><br><span class="Bold">30 mg</span><br><span class="Bold">Once</span><br><span class="Bold">Daily</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">ACTOS</span><br><span class="Bold">45 mg</span><br><span class="Bold">Once</span><br><span class="Bold">Daily</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>p ≤0.05 vs. placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" colspan="5" valign="top"><p class="First"><span class="Bold">Total Population</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=79</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=79</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=85</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=76</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">10.4</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">10.2</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">10.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="middle"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.7</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-0.3</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-0.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-0.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo (adjusted mean<a href="#footnote-9" class="Sup">*</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-1.0<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a><br>(-1.6, -0.4)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-1.0<a href="#footnote-10" class="Sup">†</a><br>(-1.6, -0.4)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-1.6<a href="#footnote-10" class="Sup">†</a><br>(-2.2, -1.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=79</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=79</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=84</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=77</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">268</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">267</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">269</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">276</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a href="#footnote-9" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-30</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-32</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-56</p></td>
</tr>
<tr class="Botrule Last">
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo (adjusted mean<a href="#footnote-9" class="Sup">*</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-39<a href="#footnote-10" class="Sup">†</a><br>(-63, -16)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-41<a href="#footnote-10" class="Sup">†</a><br>(-64, -18)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-65<a href="#footnote-10" class="Sup">†</a><br>(-89, -42)</p></td>
</tr>
</tbody>
</table>
<p>In a 24-week placebo-controlled monotherapy trial, 260 patients with type 2 diabetes were randomized to one of two forced-titration ACTOS treatment groups or a mock-titration placebo group. Therapy with any previous antidiabetic agent was discontinued six weeks prior to the double-blind period. In one ACTOS treatment group, patients received an initial dose of 7.5 mg once daily. After four weeks, the dose was increased to 15 mg once daily and after another four weeks, the dose was increased to 30 mg once daily for the remainder of the trial (16 weeks). In the second ACTOS treatment group, patients received an initial dose of 15 mg once daily and were titrated to 30 mg once daily and 45 mg once daily in a similar manner. Treatment with ACTOS, as described, produced statistically significant improvements in HbA1c and FPG at endpoint compared to placebo <span class="Italics">(see Table 18)</span>.</p>
<table>
<col width="60%">
<col width="14%">
<col width="19%">
<col width="19%">
<thead>
<tr class="First Toprule"><th class="Botrule" colspan="4">Table 18. Glycemic Parameters in a 24-Week Placebo-Controlled Forced-Titration Monotherapy Trial</th></tr>
<tr class="Last">
<th class="Botrule Lrule Toprule"></th>
<th class="Botrule Lrule Toprule"><span class="Bold">Placebo</span></th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS</span><br><span class="Bold">30 mg</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a><br><span class="Bold">Once</span><br><span class="Bold">Daily</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">ACTOS</span><br><span class="Bold">45 mg</span><a href="#footnote-11" class="Sup">*</a><br><span class="Bold">Once</span><br><span class="Bold">Daily</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>Final dose in forced titration</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">‡</a></dt>
<dd>p ≤0.05 vs. placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" colspan="4" valign="top"><p class="First"><span class="Bold">Total Population</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=83</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=85</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=85</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">10.8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">10.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-0.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-0.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo (adjusted mean<a href="#footnote-12" class="Sup">†</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-1.5<a name="footnote-reference-13" href="#footnote-13" class="Sup">‡</a><br>(-2.0, -1.0)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-1.5<a href="#footnote-13" class="Sup">‡</a><br>(-2.0, -1.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=78</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=82</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=85</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">279</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">268</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">281</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a href="#footnote-12" class="Sup">†</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">18</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-44</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-50</p></td>
</tr>
<tr class="Botrule Last">
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo (adjusted mean<a href="#footnote-12" class="Sup">†</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-62<a href="#footnote-13" class="Sup">‡</a><br>(-82, -0.41)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-68<a href="#footnote-13" class="Sup">‡</a><br>(-88, -0.48)</p></td>
</tr>
</tbody>
</table>
<p>In a 16-week monotherapy trial, 197 patients with type 2 diabetes were randomized to treatment with 30 mg of ACTOS or placebo once daily. Therapy with any previous antidiabetic agent was discontinued six weeks prior to the double-blind period. Treatment with 30 mg of ACTOS produced statistically significant improvements in HbA1c and FPG at endpoint compared to placebo <span class="Italics">(see Table 19)</span>.</p>
<table>
<col width="56%">
<col width="14%">
<col width="23%">
<thead>
<tr class="First Toprule"><th class="Botrule" colspan="3">Table 19. Glycemic Parameters in a 16-Week Placebo-Controlled Monotherapy Trial</th></tr>
<tr class="Last">
<th class="Botrule Lrule Toprule"></th>
<th class="Botrule Lrule Toprule"><span class="Bold">Placebo</span></th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">ACTOS 30 mg</span><br><span class="Bold">Once Daily</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction </dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd>p ≤0.050 vs. placebo</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" colspan="3" valign="top"><p class="First"><span class="Bold">Total Population</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=93</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=100</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">10.3</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">10.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-0.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo (adjusted mean<a href="#footnote-14" class="Sup">*</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-1.4<a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a><br>(-1.8, -0.9)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=91</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=99</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">270</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">273</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a href="#footnote-14" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-50</p></td>
</tr>
<tr class="Botrule Last">
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo (adjusted mean<a href="#footnote-14" class="Sup">*</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-58<a href="#footnote-15" class="Sup">†</a><br>(-77, -38)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_s14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Combination Therapy</h2>
<p class="First">Three 16-week, randomized, double-blind, placebo-controlled clinical trials were conducted to evaluate the effects of ACTOS (15 mg and/or 30 mg) on glycemic control in patients with type 2 diabetes who were inadequately controlled (HbA1c ≥8%) despite current therapy with a sulfonylurea, metformin, or insulin. In addition, three 24-week randomized, double-blind clinical trials were conducted to evaluate the effects of ACTOS 30 mg vs. ACTOS 45 mg on glycemic control in patients with type 2 diabetes who were inadequately controlled (HbA1c ≥8%) despite current therapy with a sulfonylurea, metformin, or insulin. Previous diabetes treatment may have been monotherapy or combination therapy.</p>
<p><span class="Bold">Add-on to Sulfonylurea Trials</span></p>
<p>Two clinical trials were conducted with ACTOS in combination with a sulfonylurea. Both studies included patients with type 2 diabetes on any dose of a sulfonylurea, either alone or in combination with another antidiabetic agent. All other antidiabetic agents were withdrawn at least three weeks prior to starting study treatment. </p>
<p>In the first study, 560 patients were randomized to receive 15 mg or 30 mg of ACTOS or placebo once daily for 16 weeks in addition to their current sulfonylurea regimen. Treatment with ACTOS as add-on to sulfonylurea produced statistically significant improvements in HbA1c and FPG at endpoint compared to placebo add-on to sulfonylurea <span class="Italics">(see Table 20)</span>.</p>
<table>
<col width="55%">
<col width="17%">
<col width="17%">
<col width="17%">
<thead>
<tr class="First Toprule"><th class="Botrule" colspan="4">Table 20. Glycemic Parameters in a 16-Week Placebo-Controlled, Add-on to Sulfonylurea Trial</th></tr>
<tr class="Last">
<th class="Botrule Lrule Toprule"></th>
<th class="Botrule Lrule Toprule">
<span class="Bold">Placebo</span><br><span class="Bold">+ Sulfonylurea</span>
</th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS 15 mg</span><br><span class="Bold">+ Sulfonylurea</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">ACTOS 30 mg</span><br><span class="Bold">+ Sulfonylurea</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">†</a></dt>
<dd>p ≤0.05 vs. placebo + sulfonylurea</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" colspan="4" valign="top"><p class="First"><span class="Bold">Total Population</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=181</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=176</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=182</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9.9</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">10.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-1.2</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo + sulfonylurea (adjusted mean<a href="#footnote-16" class="Sup">*</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-0.9<a name="footnote-reference-17" href="#footnote-17" class="Sup">†</a><br>(-1.2, -0.6)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-1.3<a href="#footnote-17" class="Sup">†</a><br>(-1.6, -1.0)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=182</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=179</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=186</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">236</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">247</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">239</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a href="#footnote-16" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">6</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-34</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-52</p></td>
</tr>
<tr class="Botrule Last">
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo + sulfonylurea (adjusted mean<a href="#footnote-16" class="Sup">*</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-39<a href="#footnote-17" class="Sup">†</a><br>(-52, -27)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-58<a href="#footnote-17" class="Sup">†</a><br>(-70, -46)</p></td>
</tr>
</tbody>
</table>
<p>In the second trial, 702 patients were randomized to receive 30 mg or 45 mg of ACTOS once daily for 24 weeks in addition to their current sulfonylurea regimen. The mean reduction from baseline at Week 24 in HbA1c was 1.6% for the 30 mg dose and 1.7% for the 45 mg dose <span class="Italics">(see <a href="#Table21">Table 21</a>)</span>. The mean reduction from baseline at Week 24 in FPG was 52 mg/dL for the 30 mg dose and 56 mg/dL for the 45 mg dose.</p>
<p>The therapeutic effect of ACTOS in combination with sulfonylurea was observed in patients regardless of the sulfonylurea dose.</p>
<table>
<col width="76%">
<col width="19%">
<col width="19%">
<thead>
<tr class="First"><th class="Botrule" colspan="3">Table 21. Glycemic Parameters in a 24-Week Add-on to Sulfonylurea Trial</th></tr>
<tr class="Last">
<th class="Botrule Lrule Toprule"></th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS 30 mg +</span><br><span class="Bold">Sulfonylurea</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">ACTOS 45 mg +</span><br><span class="Bold">Sulfonylurea</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Total Population</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=340</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=332</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-1.6</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-1.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from 30 mg daily ACTOS + sulfonylurea (adjusted mean<a href="#footnote-18" class="Sup">*</a>) (95% CI)</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-0.1<br>(-0.4, 0.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=338</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=329</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">214</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">217</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a href="#footnote-18" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-52</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-56</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from 30 mg daily ACTOS + sulfonylurea (adjusted mean<a href="#footnote-18" class="Sup">*</a>) (95% CI)</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-5<br>(-12, 3)</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="3" valign="top"><p class="First">95% CI = 95% confidence interval</p></td></tr>
</tbody>
</table>
<p><span class="Bold">Add-on to Metformin Trials</span></p>
<p>Two clinical trials were conducted with ACTOS in combination with metformin. Both trials included patients with type 2 diabetes on any dose of metformin, either alone or in combination with another antidiabetic agent. All other antidiabetic agents were withdrawn at least three weeks prior to starting study treatment. </p>
<p>In the first trial, 328 patients were randomized to receive either 30 mg of ACTOS or placebo once daily for 16 weeks in addition to their current metformin regimen. Treatment with ACTOS as add-on to metformin produced statistically significant improvements in HbA1c and FPG at endpoint compared to placebo add-on to metformin <span class="Italics">(see <a href="#Table22">Table 22</a>)</span>.</p>
<table>
<col width="64%">
<col width="18%">
<col width="20%">
<thead>
<tr class="First Toprule"><th class="Botrule" colspan="3">Table 22. Glycemic Parameters in a 16-Week Placebo-Controlled, Add-on to Metformin Trial</th></tr>
<tr class="Last">
<th class="Botrule Lrule Toprule"></th>
<th class="Botrule Lrule Toprule">
<span class="Bold">Placebo</span><br><span class="Bold">+ Metformin</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">ACTOS 30 mg</span><br><span class="Bold">+ Metformin</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-19" href="#footnote-reference-19">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">†</a></dt>
<dd>p ≤0.05 vs. placebo + metformin</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" colspan="3" valign="top"><p class="First"><span class="Bold">Total Population</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=153</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=161</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9.9</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-19" href="#footnote-19" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">0.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-0.6</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo + metformin (adjusted mean<a href="#footnote-19" class="Sup">*</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-0.8<a name="footnote-reference-20" href="#footnote-20" class="Sup">†</a><br>(-1.2, -0.5)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=157</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=165</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">260</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">254</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a href="#footnote-19" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-5</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-43</p></td>
</tr>
<tr class="Botrule Last">
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo + metformin (adjusted mean<a href="#footnote-19" class="Sup">*</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-38<a href="#footnote-20" class="Sup">†</a><br>(-49, -26)</p></td>
</tr>
</tbody>
</table>
<p>In the second trial, 827 patients were randomized to receive either 30 mg or 45 mg of ACTOS once daily for 24 weeks in addition to their current metformin regimen. The mean reduction from baseline at Week 24 in HbA1c was 0.8% for the 30 mg dose and 1.0% for the 45 mg dose <span class="Italics">(see <a href="#Table23">Table 23</a>)</span>. The mean reduction from baseline at Week 24 in FPG was 38 mg/dL for the 30 mg dose and 51 mg/dL for the 45 mg dose.</p>
<table>
<col width="75%">
<col width="19%">
<col width="17%">
<thead>
<tr class="First"><th class="Botrule" colspan="3">Table 23. Glycemic Parameters in a 24-Week Add-on to Metformin Study</th></tr>
<tr class="Last">
<th class="Botrule Lrule Toprule"></th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS 30 mg +</span><br><span class="Bold">Metformin</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">ACTOS 45 mg</span><br><span class="Bold">+ Metformin</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-21" href="#footnote-reference-21">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">†</a></dt>
<dd>p ≤0.05 vs. 30 mg daily ACTOS + metformin</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Total Population</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=400</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=398</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-21" href="#footnote-21" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-0.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-1.0</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from 30 mg daily ACTOS + Metformin (adjusted mean<a href="#footnote-21" class="Sup">*</a>) (95% CI)</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-0.2<br>(-0.5, 0.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=398</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=399</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">233</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">232</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a href="#footnote-21" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-38</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-51</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from 30 mg daily ACTOS + Metformin (adjusted mean<a href="#footnote-19" class="Sup">*</a>) (95% CI)</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-12<a name="footnote-reference-22" href="#footnote-22" class="Sup">†</a><br>(-21, -4)</p></td>
</tr>
<tr class="Last"><td class="Botrule Rrule" colspan="3" valign="top"><p class="First">95% CI = 95% confidence interval</p></td></tr>
</tbody>
</table>
<p>The therapeutic effect of ACTOS in combination with metformin was observed in patients regardless of the metformin dose.</p>
<p><span class="Bold">Add-on to Insulin Trials</span></p>
<p>Two clinical trials were conducted with ACTOS in combination with insulin. Both trials included patients with type 2 diabetes on insulin, either alone or in combination with another antidiabetic agent. All other antidiabetic agents were withdrawn prior to starting study treatment. In the first trial, 566 patients were randomized to receive either 15 mg or 30 mg of ACTOS or placebo once daily for 16 weeks in addition to their insulin regimen. Treatment with ACTOS as add-on to insulin produced statistically significant improvements in HbA1c and FPG at endpoint compared to placebo add-on to insulin <span class="Italics">(see <a href="#Table24">Table 24</a>)</span>. The mean daily insulin dose at baseline in each treatment group was approximately 70 units. The majority of patients (75% overall, 86% treated with placebo, 77% treated with ACTOS 15 mg, and 61% treated with ACTOS 30 mg) had no change in their daily insulin dose from baseline to the final study visit. The mean change from baseline in daily dose of insulin (including patients with no insulin dose modifications) was -3 units in the patients treated with ACTOS 15 mg, -8 units in the patients treated with ACTOS 30 mg, and -1 unit in patients treated with placebo.</p>
<table>
<col width="52%">
<col width="12%">
<col width="17%">
<col width="17%">
<thead>
<tr class="First Toprule"><th class="Botrule" colspan="4">Table 24. Glycemic Parameters in a 16-Week Placebo-Controlled, Add-on to Insulin Trial</th></tr>
<tr class="Last">
<th class="Botrule Lrule Toprule"></th>
<th class="Botrule Lrule Toprule">
<span class="Bold">Placebo</span><br><span class="Bold">+ Insulin</span>
</th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS 15 mg </span><br><span class="Bold">+ Insulin</span>
</th>
<th class="Botrule Lrule Rrule Toprule">
<span class="Bold">ACTOS 30 mg </span><br><span class="Bold">+ Insulin</span>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-23" href="#footnote-reference-23">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">†</a></dt>
<dd>p ≤0.05 vs. placebo + insulin</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule" colspan="4" valign="top"><p class="First"><span class="Bold">Total Population</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> N=177 </p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First"> N=177 </p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First"> N=185 </p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9.8</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9.8</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9.8</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-23" href="#footnote-23" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-0.3</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-1.0</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-1.3</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo + Insulin (adjusted mean<a href="#footnote-23" class="Sup">*</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-0.7<a name="footnote-reference-24" href="#footnote-24" class="Sup">†</a><br>(-1.0, -0.5)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-1.0<a href="#footnote-24" class="Sup">†</a><br>(-1.3, -0.7)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=179</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=183</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=184</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">221</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">222</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">229</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a href="#footnote-23" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">1</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-35</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-48</p></td>
</tr>
<tr class="Botrule Last">
<td class="Botrule Lrule" valign="top"><p class="First">Difference from placebo + Insulin (adjusted mean<a href="#footnote-23" class="Sup">*</a>)<br>95% Confidence Interval</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-35<a href="#footnote-24" class="Sup">†</a><br>(-51, -19)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-49<a href="#footnote-24" class="Sup">†</a><br>(-65, -33)</p></td>
</tr>
</tbody>
</table>
<p>In the second trial, 690 patients receiving a median of 60 units per day of insulin were randomized to receive either 30 mg or 45 mg of ACTOS once daily for 24 weeks in addition to their current insulin regimen. The mean reduction from baseline at Week 24 in HbA1c was 1.2% for the 30 mg dose and 1.5% for the 45 mg dose. The mean reduction from baseline at Week 24 in FPG was 32 mg/dL for the 30 mg dose and 46 mg/dL for the 45 mg dose <span class="Italics">(see <a href="#Table25">Table 25</a>)</span>. The mean daily insulin dose at baseline in both treatment groups was approximately 70 units. The majority of patients (55% overall, 58% treated with ACTOS 30 mg, and 52% treated with ACTOS 45 mg) had no change in their daily insulin dose from baseline to the final study visit. The mean change from baseline in daily dose of insulin (including patients with no insulin dose modifications) was -5 units in the patients treated with ACTOS 30 mg and -8 units in the patients treated with ACTOS 45 mg.</p>
<p>The therapeutic effect of ACTOS in combination with insulin was observed in patients regardless of the insulin dose.</p>
<table>
<col width="71%">
<col width="19%">
<col width="26%">
<thead>
<tr class="First"><th class="Botrule" colspan="3">Table 25. Glycemic Parameters in a 24-Week Add-on to Insulin Trial</th></tr>
<tr class="Last">
<th class="Botrule Lrule Toprule"></th>
<th class="Botrule Lrule Toprule">
<span class="Bold">ACTOS 30 mg +</span><br><span class="Bold"> Insulin </span>
</th>
<th class="Botrule Lrule Rrule Toprule"><span class="Bold">ACTOS 45 mg + Insulin</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-25" href="#footnote-reference-25">*</a></dt>
<dd>Adjusted for baseline, pooled center, and pooled center by treatment interaction</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">†</a></dt>
<dd>p ≤0.05 vs. 30 mg daily ACTOS + insulin</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td class="Botrule Lrule Rrule Toprule" colspan="3" valign="top"><p class="First"><span class="Bold">Total Population</span></p></td></tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">HbA1c (%)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=328</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=328</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">9.9</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">9.7</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a name="footnote-reference-25" href="#footnote-25" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-1.2</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-1.5</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from 30 mg daily ACTOS + Insulin (adjusted mean<a href="#footnote-25" class="Sup">*</a>) (95% CI)</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-0.3<a name="footnote-reference-26" href="#footnote-26" class="Sup">†</a><br>(-0.5, -0.1)</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First"><span class="Bold">Fasting Plasma Glucose (mg/dL)</span></p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">N=325</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">N=327</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Baseline (mean)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">202</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">199</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Change from baseline (adjusted mean<a href="#footnote-25" class="Sup">*</a>)</p></td>
<td class="Botrule Lrule" align="center" valign="top"><p class="First">-32</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-46</p></td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"><p class="First">Difference from 30 mg daily ACTOS + Insulin (adjusted mean<a href="#footnote-25" class="Sup">*</a>) (95% CI)</p></td>
<td class="Botrule Lrule" valign="top"></td>
<td class="Botrule Lrule Rrule" align="center" valign="top"><p class="First">-14<a href="#footnote-26" class="Sup">†</a><br>(-25, -3)</p></td>
</tr>
<tr class="Last"><td class="Botrule Rrule" colspan="3" valign="top"><p class="First">95% CI = 95% confidence interval </p></td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_s16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">ACTOS is available in 15 mg, 30 mg, and 45 mg tablets as follows:</p>
<p>15 mg tablet: White to off-white, round, convex, nonscored tablet with "ACTOS" on one side, and "15" on the other, available in:</p>
<p>NDC 64764-151-04 Bottles of 30 <br>NDC 64764-151-05 Bottles of 90 <br>NDC 64764-151-06 Bottles of 500</p>
<p>30 mg tablet: White to off-white, round, flat, nonscored tablet with "ACTOS" on one side, and "30" on the other, available in:</p>
<p>NDC 64764-301-14 Bottles of 30 <br>NDC 64764-301-15 Bottles of 90 <br>NDC 64764-301-16 Bottles of 500</p>
<p>45 mg tablet: White to off-white, round, flat, nonscored tablet with "ACTOS" on one side, and "45" on the other, available in:</p>
<p>NDC 64764-451-24 Bottles of 30 <br>NDC 64764-451-25 Bottles of 90 <br>NDC 64764-451-26 Bottles of 500</p>
<p><span class="Bold">Storage</span></p>
<p>Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature]. Keep container tightly closed, and protect from light, moisture and humidity.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_s17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">See FDA-Approved Patient Labeling (Medication Guide).</p>
<dl>
<dt>•</dt>
<dd>It is important to instruct patients to adhere to dietary instructions and to have blood glucose and <span class="product-label-link" type="condition" conceptid="4123836" conceptname="Glycosylated hemoglobin">glycosylated hemoglobin</span> tested regularly. During periods of stress such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, or surgery, medication requirements may change and patients should be reminded to seek medical advice promptly.</dd>
<dt>•</dt>
<dd>Patients who experience an unusually rapid increase in weight or <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> or who develop <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or other symptoms of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> while on ACTOS should immediately report these symptoms to a physician.</dd>
<dt>•</dt>
<dd>Tell patients to promptly stop taking ACTOS and seek immediate medical advice if there is unexplained <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, or dark urine as these symptoms may be due to hepatotoxicity. </dd>
<dt>•</dt>
<dd>Tell patients to promptly report any sign of <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">macroscopic hematuria</span> or other symptoms such as <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">dysuria</span> or <span class="product-label-link" type="condition" conceptid="200845" conceptname="Urgent desire to urinate">urinary urgency</span> that develop or increase during treatment as these may be due to <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>.</dd>
<dt>•</dt>
<dd>Tell patients to take ACTOS once daily. ACTOS can be taken with or without meals. If a dose is missed on one day, the dose should not be doubled the following day.</dd>
<dt>•</dt>
<dd>When using combination therapy with insulin or other antidiabetic medications, the risks of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and their family members.</dd>
<dt>•</dt>
<dd>Inform patients that therapy with ACTOS, like other thiazolidinediones, may result in ovulation in some premenopausal anovulatory women. As a result, these patients may be at an increased risk for pregnancy while taking ACTOS. Therefore, adequate contraception should be recommended for all premenopausal women who are prescribed ACTOS.</dd>
</dl>
<p>Distributed by:<br><span class="Bold">Takeda Pharmaceuticals America, Inc.</span><br>Deerfield, IL 60015</p>
<p>ACTOS is a trademark of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>©1999 - 2013 Takeda Pharmaceuticals America, Inc. </p>
<p>ACT003 R20</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="i4i_medguide_id_85d35a66-efc0-47ae-a03b-cbbe467d0af2"></a><a name="section-16"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">ACTOS (ak-TŌS)</span><br><span class="Bold">(pioglitazone) tablets</span></p>
<p>Read this Medication Guide carefully before you start taking ACTOS and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about ACTOS, ask your doctor or pharmacist.</p>
<p><span class="Bold">What is the most important information I should know about ACTOS?</span></p>
<p><span class="Bold">ACTOS can cause serious side effects, including new or worse <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>.</span></p>
<dl>
<dt>•</dt>
<dd>ACTOS can cause your body to keep extra fluid (<span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>), which leads to <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) and <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>. Extra body fluid can make some heart problems worse or lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span>. <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span> means your heart does not pump blood well enough</dd>
<dt>•</dt>
<dd>Do not take ACTOS if you have severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></dd>
<dt>•</dt>
<dd>If you have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> with symptoms (such as <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>), even if these symptoms are not severe, ACTOS may not be right for you</dd>
</dl>
<p><span class="Bold">Call your doctor right away if you have any of the following:</span></p>
<dl>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> or <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>, especially in the ankles or legs</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or trouble breathing, especially when you lie down</dd>
<dt>•</dt>
<dd>an unusually fast increase in weight</dd>
<dt>•</dt>
<dd>unusual <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
</dl>
<p>ACTOS can have other serious side effects. See "What are the possible side effects of ACTOS?"</p>
<p><span class="Bold">What is ACTOS?</span></p>
<p>ACTOS is a prescription medicine used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS is a diabetes medicine called pioglitazone that may be taken alone or with other diabetes medicines.</p>
<p>It is not known if ACTOS is safe and effective in children under the age of 18.</p>
<p>ACTOS is not recommended for use in children.</p>
<p>ACTOS is not for people with type 1 diabetes.</p>
<p>ACTOS is not for people with <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span> (increased <span class="product-label-link" type="condition" conceptid="4017413" conceptname="Acetoacetate">ketones</span> in your blood or urine).</p>
<p><span class="Bold">Who should not take ACTOS?</span></p>
<p>See "What is the most important information I should know about ACTOS?"</p>
<p><span class="Bold">Do not take ACTOS if you:</span></p>
<dl>
<dt>•</dt>
<dd>have severe <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></dd>
<dt>•</dt>
<dd>are allergic to any of the ingredients in ACTOS<span class="Bold">. </span>See the end of this Medication Guide for a complete list of ingredients in ACTOS</dd>
</dl>
<p>Talk to your doctor before taking ACTOS if you have either of these conditions.</p>
<p><span class="Bold">What should I tell my doctor before taking ACTOS?</span></p>
<p>Before you take ACTOS, tell your doctor if you:</p>
<dl>
<dt>•</dt>
<dd><span class="Bold">have <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span></span></dd>
<dt>•</dt>
<dd><span class="Bold">have type 1 ("juvenile") diabetes or had <span class="product-label-link" type="condition" conceptid="443727" conceptname="Diabetic ketoacidosis">diabetic ketoacidosis</span></span></dd>
<dt>•</dt>
<dd><span class="Bold">have a type of diabetic eye disease that causes <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the back of the eye (<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>)</span></dd>
<dt>•</dt>
<dd><span class="Bold">have liver problems</span></dd>
<dt>•</dt>
<dd><span class="Bold">have or have had cancer of the bladder</span></dd>
<dt>•</dt>
<dd>
<span class="Bold">are pregnant or plan to become pregnant.</span> It is not known if ACTOS will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant about the best way to control your blood glucose levels while pregnant</dd>
<dt>•</dt>
<dd>
<span class="Bold">are a premenopausal woman (before the "change of life") who does not have periods regularly or at all. </span>ACTOS may increase your chance of becoming pregnant. Talk to your doctor about birth control choices while taking ACTOS. Tell your doctor right away if you become pregnant while taking ACTOS</dd>
<dt>•</dt>
<dd>
<span class="Bold">are breastfeeding or plan to breastfeed.</span> It is not known if ACTOS passes into your milk and if it can harm your baby. You should not take ACTOS if you breastfeed your baby. Talk to your doctor about the best way to control your blood glucose levels while breastfeeding</dd>
</dl>
<p><span class="Bold">Tell your doctor about all the medicines you take</span> including prescription and over the counter medicines, vitamins, and herbal supplements. </p>
<p>ACTOS and some of your other medicines can affect each other. You may need to have your dose of ACTOS or certain other medicines changed. </p>
<p>Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist before you start a new medicine. They will tell you if it is okay to take ACTOS with other medicines.</p>
<p><span class="Bold">How should I take ACTOS?</span></p>
<dl>
<dt>•</dt>
<dd>Take ACTOS exactly as your doctor tells you to take it</dd>
<dt>•</dt>
<dd>Your doctor may change your dose of ACTOS. Do not change your ACTOS dose unless your doctor tells you to</dd>
<dt>•</dt>
<dd>ACTOS may be prescribed alone or with other diabetes medicines. This will depend on how well your blood sugar is controlled</dd>
<dt>•</dt>
<dd>Take ACTOS one time each day, with or without food</dd>
<dt>•</dt>
<dd>If you miss a dose of ACTOS, take your next dose as prescribed unless your doctor tells you differently. Do not take two doses at one time the next day</dd>
<dt>•</dt>
<dd>If you take too much ACTOS, call your doctor or go to the nearest hospital emergency room right away</dd>
<dt>•</dt>
<dd>If your body is under stress such as from a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, or surgery the dose of your diabetes medicines may need to be changed. Call your doctor right away</dd>
<dt>•</dt>
<dd>Stay on your diet and exercise programs and test your blood sugar regularly while taking ACTOS</dd>
<dt>•</dt>
<dd>Your doctor should do certain blood tests before you start and while you take ACTOS</dd>
<dt>•</dt>
<dd>Your doctor should also do hemoglobin A1C testing to check how well your blood sugar is controlled with ACTOS</dd>
<dt>•</dt>
<dd>Your doctor should check your eyes regularly while you take ACTOS</dd>
</dl>
<p><span class="Bold">What are the possible side effects of ACTOS?</span></p>
<p><span class="Bold">ACTOS may cause serious side effects including:</span></p>
<dl>
<dt>•</dt>
<dd><span class="Bold">See "What is the most important information I should know about ACTOS?"</span></dd>
<dt>•</dt>
<dd>
<span class="Bold">low blood sugar (<span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>). </span>This can happen if you skip meals, if you also use another medicine that lowers blood sugar, or if you have certain medical problems. <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shakiness</span>, or <span class="product-label-link" type="condition" conceptid="4205415" conceptname="Hungry">hunger</span> may happen if your blood sugar is too low. Call your doctor if low blood sugar levels are a problem for you</dd>
<dt>•</dt>
<dd>
<span class="Bold">liver problems.</span> Call your doctor right away if you have:<dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach pain</span></dd>
<dt>o</dt>
<dd>unusual or unexplained <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></dd>
<dt>o</dt>
<dd>loss of appetite</dd>
<dt>o</dt>
<dd>dark urine</dd>
<dt>o</dt>
<dd>yellowing of your skin or the whites of your eyes</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>.</span> There may be an increased chance of having <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span> when you take ACTOS. You should not take ACTOS if you are receiving treatment for <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>. Tell your doctor right away if you have any of the following symptoms of <span class="product-label-link" type="condition" conceptid="73153" conceptname="Malignant neoplasm of lateral wall of urinary bladder">bladder cancer</span>:<dl>
<dt>o</dt>
<dd>blood or a red color in your urine</dd>
<dt>o</dt>
<dd>an increased need to urinate</dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> while you urinate</dd>
</dl>
</dd>
<dt>•</dt>
<dd>
<span class="Bold">broken bones (<span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>). </span>Usually in the hand, upper arm, or foot in women. Talk to your doctor for advice on how to keep your bones healthy.</dd>
<dt>•</dt>
<dd>
<span class="Bold">diabetic eye disease with <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> in the back of the eye (<span class="product-label-link" type="condition" conceptid="4290333" conceptname="Macular retinal edema">macular edema</span>).</span> Tell your doctor right away if you have any changes in your vision. Your doctor should check your eyes regularly</dd>
<dt>•</dt>
<dd>
<span class="Bold">release of an egg from an ovary in a woman (ovulation) leading to pregnancy. </span>Ovulation may happen when premenopausal women who do not have regular monthly periods take ACTOS. This can increase your chance of getting pregnant</dd>
</dl>
<p>The most common side effects of ACTOS include:</p>
<dl>
<dt></dt>
<dd><dl>
<dt></dt>
<dd><dl>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span>-like symptoms (<span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>)</dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span></dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinus infection</span></dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span></dd>
<dt>o</dt>
<dd><span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span></dd>
</dl></dd>
</dl></dd>
</dl>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all the side effects of ACTOS. For more information, ask your doctor or pharmacist. </p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store ACTOS?</span></p>
<dl>
<dt>•</dt>
<dd>Store ACTOS at 68°F to 77°F (20°C to 25°C). Keep ACTOS in the original container and protect from light</dd>
<dt>•</dt>
<dd>Keep the ACTOS bottle tightly closed and keep tablets dry</dd>
<dt>•</dt>
<dd>Keep ACTOS and all medicines out of the reach of children</dd>
</dl>
<p><span class="Bold">General information about the safe and effective use of ACTOS</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ACTOS for a condition for which it was not prescribed. Do not give ACTOS to other people, even if they have the same symptoms you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about ACTOS. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about ACTOS that is written for healthcare professionals. For more information, go to www.actos.com or call 1-877-825-3327.</p>
<p><span class="Bold">What are the ingredients in ACTOS?</span></p>
<p>Active Ingredient: pioglitazone</p>
<p>Inactive Ingredients: lactose monohydrate, hydroxypropylcellulose, carboxymethylcellulose calcium, and magnesium stearate</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Distributed by:<br><span class="Bold">Takeda Pharmaceuticals America, Inc.</span><br>Deerfield, IL 60015</p>
<p>Revised: November 2013</p>
<p>ACTOS is a trademark of Takeda Pharmaceutical Company Limited registered with the U.S. Patent and Trademark Office and used under license by Takeda Pharmaceuticals America, Inc.</p>
<p>© 2009-2013 Takeda Pharmaceuticals America, Inc.</p>
<p>ACT003 R20</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_58016f05-8f95-4e9a-acc1-8d2ef948c270"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 15 mg Bottle Label</span></p>
<p><span class="Bold">NDC</span> 64764-151-06<br>500 Tablets</p>
<p><span class="Bold">actos</span><br>(pioglitazone)<br>Tablets</p>
<p><span class="Bold">15 mg</span></p>
<p>Each tablet contains pioglitazone<br>hydrochloride equivalent to 15 mg<br>pioglitazone.</p>
<p><span class="Bold"><span class="Italics">Dispense with Medication Guide</span></span><br><span class="Bold"><span class="Italics">available in package insert or at</span></span><br><span class="Bold"><span class="Italics">www.actos.com</span></span></p>
<p><span class="Bold"><span class="Italics">Takeda logo</span></span></p>
<p><span class="Bold">Rx Only</span></p>
<span class="Bold"><div class="Figure">
<a name="id1928605"></a><img alt="Actos 15mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c&amp;name=352f5dd8-4c3e-4e8e-8167-bf383bd95dd6-03.jpg">
</div></span>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_83ccd86b-fea1-442b-b700-fda7841abaef"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 30 mg Bottle Label</span></p>
<p><span class="Bold">NDC</span> 64764-301-16<br>500 Tablets</p>
<p><span class="Bold">actos</span><br>(pioglitazone)<br>Tablets</p>
<p><span class="Bold">30 mg</span></p>
<p>Each tablet contains pioglitazone<br>hydrochloride equivalent to 30 mg<br>pioglitazone.</p>
<p><span class="Bold"><span class="Italics">Dispense with Medication Guide</span></span><br><span class="Bold"><span class="Italics">available in package insert or at</span></span><br><span class="Bold"><span class="Italics">www.actos.com</span></span></p>
<p><span class="Bold"><span class="Italics">Takeda logo</span></span></p>
<p><span class="Bold">Rx Only</span></p>
<span class="Bold"><div class="Figure">
<a name="id1928609"></a><img alt="Actos 30mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c&amp;name=352f5dd8-4c3e-4e8e-8167-bf383bd95dd6-04.jpg">
</div></span>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_7e8515ce-4227-4dc1-9615-ca0f07fb0762"></a><a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 45 mg Bottle Label</span></p>
<p><span class="Bold">NDC</span> 64764-451-26<br>500 Tablets</p>
<p><span class="Bold">Actos</span></p>
<p>(pioglitazone)<br>Tablets</p>
<p><span class="Bold">45 mg</span></p>
<p>Each tablet contains pioglitazone<br>hydrochloride equivalent to 45 mg<br>pioglitazone.</p>
<p><span class="Bold"><span class="Italics">Dispense with Medication Guide</span></span><br><span class="Bold"><span class="Italics">available in package insert or at</span></span><br><span class="Bold"><span class="Italics">www.actos.com</span></span></p>
<p><span class="Bold"><span class="Italics">Takeda logo</span></span></p>
<p><span class="Bold">Rx Only</span></p>
<span class="Bold"><div class="Figure">
<a name="id1928615"></a><img alt="Actos 45mg Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d2ddc491-88a9-4063-9150-443b4fa4330c&amp;name=352f5dd8-4c3e-4e8e-8167-bf383bd95dd6-05.jpg">
</div></span>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACTOS 		
					</strong><br><span class="contentTableReg">pioglitazone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-151</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PIOGLITAZONE HYDROCHLORIDE</strong> (pioglitazone) </td>
<td class="formItem">pioglitazone</td>
<td class="formItem">15 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carboxymethylcellulose calcium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round, convex) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACTOS;15</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-151-04</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-151-05</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-151-06</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-151-02</td>
<td class="formItem">6  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021073</td>
<td class="formItem">07/15/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACTOS 		
					</strong><br><span class="contentTableReg">pioglitazone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-301</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PIOGLITAZONE HYDROCHLORIDE</strong> (pioglitazone) </td>
<td class="formItem">pioglitazone</td>
<td class="formItem">30 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carboxymethylcellulose calcium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round, flat) </td>
<td class="formLabel">Size</td>
<td class="formItem">7mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACTOS;30</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-301-14</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-301-15</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-301-16</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-301-02</td>
<td class="formItem">6  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021073</td>
<td class="formItem">07/15/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACTOS 		
					</strong><br><span class="contentTableReg">pioglitazone tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:64764-451</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PIOGLITAZONE HYDROCHLORIDE</strong> (pioglitazone) </td>
<td class="formItem">pioglitazone</td>
<td class="formItem">45 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carboxymethylcellulose calcium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYDROXYPROPYL CELLULOSE (TYPE H)</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND (round, flat) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ACTOS;45</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:64764-451-24</td>
<td class="formItem">30  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:64764-451-25</td>
<td class="formItem">90  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:64764-451-26</td>
<td class="formItem">500  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:64764-451-02</td>
<td class="formItem">6  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem"></td>
<td class="formItem">7  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021073</td>
<td class="formItem">07/15/1999</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Takeda Pharmaceuticals America, Inc.
							(830134016)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Takeda Pharmaceutical Company Limited, Osaka Plant</td>
<td class="formItem"></td>
<td class="formItem">695132274</td>
<td class="formItem">ANALYSIS(64764-151, 64764-301, 64764-451), MANUFACTURE(64764-151, 64764-301, 64764-451)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>352f5dd8-4c3e-4e8e-8167-bf383bd95dd6</div>
<div>Set id: d2ddc491-88a9-4063-9150-443b4fa4330c</div>
<div>Version: 12</div>
<div>Effective Time: 20131121</div>
</div>
</div> <div class="DistributorName">Takeda Pharmaceuticals America, Inc.</div></p>
</body></html>
